Document:

Second Amended and Restated Investors' Rights Agreement

 Exhibit 4.4 
 LOYALTY ALLIANCE ENTERPRISE CORPORATION 
 SECOND AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this
“Agreement”) is entered into and made effective as of December 2, 2011 (the “Effective Date”), by and among Loyalty Alliance Enterprise Corporation, a Cayman Islands company, (the “Company”),
the persons and entities listed on Exhibit A attached herein as holders of Series A Preference Shares of the Company (the “Series A Holders”), the persons and entities listed on Exhibit B attached herein
as holders of Series B Preference Shares of the Company (the “Series B Holders”), the persons and entities listed on Exhibit C attached herein as holders of Series C Preference Shares of the Company (the
“Series C Holders”), the persons and entities listed on Exhibit D attached herein as holders of Series D Preference Shares of the Company (the “Series D Holders”), the persons and entities
listed on Exhibit E attached herein as holders of Series E Preference Shares of the Company, (the “Series E Holders”), the persons and entities listed on Exhibit F attached herein as holders of
Series F Preference Shares of the Company (the “Series F Holders”), the persons and entities listed on Exhibit G attached herein as holders of Series G Preference Shares of the Company (the “Series G
Holders”), the persons and entities listed on Exhibit H attached hereto as holders of the subordinated convertible promissory notes (the “Notes”) issued by the Company on the date hereof (the “Note
Holders”), and the persons and entities listed on Exhibit I attached herein as holders of Ordinary Shares of the Company (the “Ordinary Holders”), as the same may be amended from time to time in accordance with the
provisions of this Agreement. The Series A Preference Shares, Series B Preference Shares, Series C Preference Shares, Series D Preference Shares, Series E Preference Shares, Series F Preference Shares and Series G Preference Shares shall be referred
to collectively as the “Preference Shares.” The Series A Holders, Series B Holders, Series C Holders, Series D Holders, Series E Holders, Series F Holders, Series G Holders and the Note Holders shall be referred to collectively as
the “Investors,” and each individually as an “Investor,” and the Investors and Ordinary Holders shall be referred to collectively as the “Shareholders,” and each individually, as a
“Shareholder.” 
 RECITALS 

WHEREAS, concurrently herewith, the Company is issuing the Notes to the Note Holders; and 

WHEREAS, it is a condition to the issuance of the Notes that the Note Holders and the other parties heretoexecute and deliver this
Agreement. 

  
 1 

 NOW THEREFORE, in consideration of these premises and for other good and valid
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 1.
INFORMATION AND REGISTRATION RIGHTS. 
 1.1 Certain Definitions. 

As used in this Agreement, the following terms shall have the following respective meanings: 

(a) “Commission” shall mean the Securities and Exchange Commission or any other agency at the time administering the
Securities Act. 
 (b) “Convertible Securities” shall mean securities of the Company convertible into or
exchangeable for Ordinary Shares of the Company. For the avoidance of doubt, such securities shall include the Notes. 
 (c)
“Form F-3/S-3” shall mean Form F-3 or Form S-3 issued by the Commission or any substantially similar form then in effect. 
 (d) “Group” shall mean the Company and its subsidiaries. 
 (e)
“Holder” shall mean any holder of outstanding Registrable Securities which have not been sold to the public, but only if such holder is an Investor, an Ordinary Holder, or an assignee or transferee of Registration rights as
permitted by Section 1.12. 
 (f) “Initiating Holders” shall mean Holders who in the aggregate hold at
least twenty percent (20%) of the Registrable Securities. 
 (g) “IPO” shall mean the Company’s
first firm commitment underwritten public offering of any of its securities to the general public pursuant to a Registration Statement filed under (i) the Securities Act (as defined below), or (ii) the securities laws applicable to an
offering of securities in another jurisdiction to which such securities will be listed on an internationally-recognized securities exchange. 
 (h) “Major Shareholder” shall mean an Investor or Ordinary Holder, or its transferee holding not less than 125,000 Ordinary Shares or shares of the Convertible Securities of the Company
originally issued (or an equivalent number of shares consisting of Registrable Securities issued upon conversion or exercise of the Convertible Securities of the Company or a combination of such Registrable Securities and such Convertible
Securities), as adjusted for recapitalizations, share splits, share dividends and the like. 
 (i) “Material Adverse
Event” shall mean an occurrence having a consequence that either: (i) is materially adverse as to the business, properties, prospects or financial condition of the Company; or (ii) is reasonably foreseeable, has a reasonable
likelihood of occurring, and if it were to occur, might materially adversely affect the business, properties, prospects or financial condition of the Company. 

  
 2 

 (j) “Merger” the consummation of any consolidation, merger, amalgamation,
scheme of arrangement, tender of shares by the Company’s Shareholders, acquisition of shares (other than a bona fide equity financing) or similar transaction or series of related transactions in which, in the case of a merger or consolidation,
the Company is one of the constituent entities or, in any such case, the Company is a party if, as a result of such transaction, the voting securities of the Company that are outstanding immediately prior to the consummation of such transaction do
not represent, or are not converted into, securities of the surviving entity of such transaction (or such surviving entity’s parent entity if the surviving entity is owned by the parent entity) that, immediately after the consummation of such
transaction, together possess at least a majority of the total voting power of all securities of such surviving entity (or its parent entity, if applicable) that are outstanding immediately after the consummation of such transaction. 

(k) The terms “Register,” “Registered” and “Registration” refer to a registration
effected by preparing and filing a registration statement in compliance with the Securities Act (“Registration Statement”), and the declaration or ordering of the effectiveness of such Registration Statement. 

(l) “Registrable Securities” shall mean the Company’s Ordinary Shares issued to Ordinary Holders and Investors, as
well as the Company’s Ordinary Shares issued or issuable upon conversion or exercise of any of the Company’s Convertible Securities purchased by or issued to the Investors, including Ordinary Shares issued pursuant to share splits, share
dividends and similar distributions, and any securities of the Company granted registration rights pursuant to Section 1.12 of this Agreement, so long as such Ordinary Shares have not been sold to the public in a public distribution or a public
securities transaction or sold in a single transaction exempt from the registration and prospectus delivery requirements of the Securities Act such that all transfer restrictions and restrictive legends with respect to such shares shall have been
removed in connection with such sale. 
 (m) “Registration Expenses” shall mean all expenses incurred by the
Company in complying with Sections 1.5 or 1.6 of this Agreement, including, without limitation, all federal, state, or foreign registration, qualification and filing fees, printing expenses, fees and disbursements of counsel for the Company and
one special counsel for Holders (if different from the Company), blue sky fees and expenses, and the expense of any special audits incident to or required by any such registration, excluding underwriters’ discounts and commissions. 

(n) “Securities Act” shall mean the Securities Act of 1933, as amended, or any similar federal statute, and the rules
and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 (o) “Selling
Expenses” shall mean all underwriting discounts and selling commissions applicable to the sale of Registrable Securities pursuant to this Agreement. 
 1.2 Financial Statements and Reports to Shareholders. 
 The Company will
deliver to each Major Shareholder: 
 (a) within 90 days after each financial year (the “FY”), the annual
audited consolidated accounts of the Company along with the annual audited accounts of each company in the Group as at the end of FY; 

  
 3 

 (b) within 30 days after end of each calendar month, the monthly management accounts of the
Company and each company in the Group; and monthly operation reports (including sales, recruitment of employees, milestone schedules, business plans, projections, and forecasts); 

(c) within 45 days after end of each quarter of each FY, the quarterly management accounts of the Company and each company in the Group;
and 
 (d) at least 30 days before the end of each FY, the annual budget, profit forecast and operating plan for the next FY.

 1.3 Additional Information. 
 The Company will deliver to each Major Shareholder prompt notice of (i) any default by the Company under any material agreement to which the Company is a party and (ii) any material litigation
to which the Company is a party or its assets are subject. 
 1.4 Use of Information; Termination of Covenants.

 (a) Investor Covenant; Termination. No Investor shall enter into any transaction for the purchase or sale of any
securities of the Company with any other person unless such Investor has made any material information actually obtained by such Investor pursuant to Sections 1.2 or 1.3 available to such other person. The covenants of the Company set forth in
Sections 1.2 or 1.3 shall be terminated and be of no further force or effect upon the earlier of (i) the IPO or (ii) the date the Company registers any securities under the Exchange Act (as defined below). 

(b) Rule 144 Reporting. With a view to making available to Holders the benefits of certain rules and regulations of the
Commission which may permit the sale of the Registrable Securities to the public without registration, the Company agrees at all times after ninety (90) days after the effective date of the first registration filed by the Company for an
offering of its securities to the general public to: 
 (i) make and keep public information available as those terms are
understood and defined in Rule 144 under the Securities Act; 
 (ii) use its commercially reasonable efforts to file with
the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”); and 

(iii) so long as a Holder owns any Registrable Securities, to furnish to such Holder forthwith upon request a written statement by the
Company as to its compliance with the reporting requirements of said Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company for an offering of its securities to the
general public) and of the Exchange Act (at any time after it has become subject to such reporting requirements), a copy of the most recent annual or quarterly report of the Company, and such other reports and documents so filed by the Company as
the Holder may reasonably request in complying with any rule or regulation or the Commission allowing the Holder to sell any such securities without registration. 

  
 4 

 1.5 Demand Registration. 

(a) Request for Registration on Form Other Than Form F-3/S-3. Subject to the terms of this Agreement, in the event that the
Company shall receive from the Initiating Holders at any time after the earlier of (i) the date five (5) years from the date of this Agreement, or (ii) six months from the Company’s IPO, a written request that the Company effect
any Registration with respect to all or a part of the Registrable Securities on a Form other than Form F-3/S-3 for an offering of at least twenty percent (20%) of the then outstanding Registrable Securities held by the Investors (or any
lesser percent if the reasonably anticipated aggregate offering price to the public would exceed Ten Million Dollars ($10,000,000)), the Company shall: (i) promptly (but in any event within ten (10) days after the receipt of such written
request) give written notice of the proposed Registration to all other Holders; and (ii) as soon as practicable, use its best efforts to effect Registration of the Registrable Securities specified in such request, together with any Registrable
Securities of any Holder joining in such request as are specified in a written request given within twenty (20) days after written notice from the Company. The Company shall not be obligated to take any action to effect any such Registration
pursuant to this Section 1.5(a): (A) within six (6) months of the effective date of a Registration initiated by the Company; or (B) after the Company has effected two such Registrations pursuant to this Section 1.5(a) and
such Registrations have been declared effective. 
 (b) Right of Deferral. Notwithstanding the foregoing, the Company
shall not be obligated to file a Registration Statement pursuant to this Section 1.5: (i) within six months immediately following the effective date of any Registration Statement pertaining to the securities of the Company (other than a
registration of securities in a Rule 145 transaction or with respect to an employee benefit plan); or (ii) if the Company shall furnish to such Holders a certificate signed by the President of the Company stating that in the good faith
judgment of the Board of Directors it would be seriously detrimental to the Company or its shareholders for a Registration Statement to be filed in the near future, then the Company’s obligation to use all reasonable efforts to file a
Registration Statement shall be deferred for a period not to exceed 60 days from the receipt of the request to file such Registration Statement by such Holder provided that the Company shall not exercise the right contained in this
paragraph (b) more than once in any 24 month period. 
 (c) Request for Registration on Form F-3/S-3. Subject
to the terms of this Agreement, in the event that the Company receives from the Holders a written request that the Company effect any Registration on Form F-3/S-3 (or any successor form to Form F-3/S-3 regardless of its designation) at a
time when the Company is eligible to Register securities on Form F-3/S-3 (or any successor form to Form F-3/S-3 regardless of its designation) for an offering of Registrable Securities the reasonably anticipated aggregate sale price to the
public of which would exceed One Million Dollars ($1,000,000), the Company will promptly give written notice of the proposed Registration to all the Holders and will as soon as practicable use its best efforts to effect Registration of the
Registrable Securities specified in such request, together with all or such portion of the Registrable Securities of any Holder joining in such request as are specified in a written request delivered to the Company within thirty (30) days after
written notice from the Company of the proposed Registration. There shall be no limit to the number of occasions on which the Company shall be obligated to effect Registration under this Section 1.5(c); provided, that the Company shall not be
obligated to take any action pursuant to this Section 1.5(c) more than once in any twelve (12) month period. 

  
 5 

 (d) Registration of Other Securities in Demand Registration. Any Registration
Statement filed pursuant to the request of the Initiating Holders under this Section 1.5 may, subject to the provisions of Section 1.5(e), include securities of the Company other than Registrable Securities. 

(e) Underwriting in Demand Registration. 
 (i) Notice of Underwriting. If in a Registration under Sections 1.5(a) or 1.5(c) the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an
underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 1.5, and the Company shall include such information in the written notice referred to in Sections 1.5(a) or 1.5(c). The right of any
Holder to Registration pursuant to Section 1.5 shall be conditioned upon such Holder’s agreement to participate in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting. 

(ii) Inclusion of Other Holders in Demand Registration. If the Company or holders of securities other than Registrable
Securities, request inclusion in such Registration, the Initiating Holders, as the case may be, to the extent they deem advisable and consistent with the goals of such Registration, shall, on behalf of all Holders, offer to any or all of the Company
or such holders of securities other than Registrable Securities that such securities other than Registrable Securities be included in the underwriting and may condition such offer on the acceptance by such persons of the terms of this
Section 1.5. In the event, however, that the number of shares so included exceeds the number of shares of Registrable Securities included by all Holders, such Registration shall be treated as governed by Section 1.6 hereof rather than
Section 1.5, and it shall not count as a Registration for purposes of Section 1.5(a) hereof. 
 (iii) Selection of
Underwriter in Demand Registration. The Company shall (together with all Holders proposing to distribute their securities through such underwriting) enter into an underwriting agreement with the representative (“Underwriter’s
Representative”) of the underwriter or underwriters selected for such underwriting by the Holders of a majority of the Registrable Securities being registered by the Initiating Holders, and agreed to by the Company. 

  
 6 

 (iv) Marketing Limitation in Demand Registration. In the event the
Underwriter’s Representative advises the Initiating Holders in writing that market factors (including, without limitation, the aggregate number of Ordinary Shares requested to be Registered, the general condition of the market, and the status
of the persons proposing to sell securities pursuant to the Registration) require a limitation of the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders and the number of shares of Registrable Securities
that may be included in the Registration and underwriting shall be allocated among all Holders in proportion, as nearly as practicable, to the respective amounts of Registrable Securities entitled to inclusion in such Registration held by such
Holders at the time of filing the Registration Statement; provided, however, that all securities other than Registrable Securities shall first be excluded from such Registration before any Registrable Securities are excluded; and provided, further,
that all Registrable Securities held by Holders other than Series E Holders, Series F Holders or Series G Holders shall first be excluded from such Registration before any Registrable Securities held by Series E Holders, Series F
Holders or Series G Holders are excluded. No Registrable Securities or other securities excluded from the underwriting by reason of this Section 1.5(e)(iv) shall be included in such Registration Statement. 

(v) Right of Withdrawal in Demand Registration. If any Holder of Registrable Securities, or a holder of other securities entitled
(upon request) to be included in such Registration, disapproves of the terms of the underwriting, such person may elect to withdraw therefrom by written notice to the Company, the underwriter and the Initiating Holders, as the case may be, delivered
at least seven (7) days prior to the effective date of the Registration Statement. The securities so withdrawn shall also be withdrawn from the Registration Statement. 
 (f) Blue Sky in Demand Registration. In the event of any Registration pursuant to Section 1.5, the Company will exercise its commercially reasonable efforts to Register and qualify the
securities covered by the Registration Statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably appropriate for the distribution of such securities; provided, however, that: (i) the Company shall not
be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions; and (ii) notwithstanding anything in this Agreement to the contrary, in the event any jurisdiction in which the
securities shall be qualified imposes a non-waivable requirement that expenses incurred in connection with the qualification of the securities be borne by selling shareholders, such expenses shall be payable pro rata by selling shareholders.

 1.6 Piggyback Registration. 
 (a) Notice of Piggyback Registration and Inclusion of Registrable Securities. Subject to the terms of this Agreement, in the event the Company decides to Register any of its Ordinary Shares (either
for its own account or the account of a security holder or holders) on a form that would be suitable for a registration involving solely Registrable Securities, the Company will: 

(i) promptly give each Holder written notice thereof (which shall include a list of the jurisdictions in which the Company intends to
attempt to qualify such securities under the applicable Blue Sky or other state securities laws); and 
 (ii) include in such
Registration (and any related qualification under Blue Sky laws or other compliance), and in any underwriting involved therein, all the Registrable Securities specified in a written request delivered to the Company by any Holder within fifteen
(15) days after delivery of such written notice from the Company. 

  
 7 

 (b) Underwriting in Piggyback Registration. 

(i) Notice of Underwriting in Piggyback Registration. If the Registration of which the Company gives notice is for a Registered
public offering involving an underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section 1.6(a). In such event the right of any Holder to Registration shall be conditioned upon such
underwriting and the inclusion of such Holder’s Registrable Securities in such underwriting to the extent provided in this Section 1.6. All Holders proposing to distribute their securities through such underwriting shall (together with the
Company and the other holders distributing their securities through such underwriting) enter into an underwriting agreement with the Underwriter’s Representative for such offering. The Holders shall have no right to participate in the selection
of the underwriters for an offering pursuant to this Section 1.6. 
 (ii) Marketing Limitation in Piggyback
Registration. In the event the Underwriter’s Representative advises the Holders seeking registration of Registrable Securities pursuant to Section 1.6 in writing that market factors (including, without limitation, the aggregate number
of Ordinary Shares requested to be Registered and the general condition of the market) require a limitation of the number of shares to be underwritten, the Underwriter’s Representative (subject to the allocation priority set forth in
Section 1.6(b)(iii)) may limit the number of shares of Registrable Securities to be included in such Registration and underwriting to not less than fifty percent (50%) of the securities included in such Registration (based on aggregate
market values) other than the Company’s IPO or zero percent (0%), or a full cutback, in the case of the Company’s IPO. 
 (iii) Allocation of Shares in Piggyback Registration. In the event that the Underwriter’s Representative limits the number of shares to be included in a Registration pursuant to
Section 1.6(b)(ii), the number of shares that may be included in the Registration and underwriting shall be allocated among all Holders thereof requesting and legally entitled to include shares in such Registration, in proportion, as nearly as
practicable, to the respective amounts of Registrable Securities which such Holders would otherwise be entitled to include in such Registration; provided, however, that all securities other than Registrable Securities shall first be excluded from
such Registration before any Registrable Securities are excluded; and, provided, further, that all Registrable Securities held by Holders other than Series E Holders, Series F Holders or Series G Holders shall first be excluded from such
Registration before any Registrable Securities held by Series E Holders, Series F Holders or Series G Holders are excluded. No Registrable Securities or other securities excluded from the underwriting by reason of this
Section 1.6(b)(iii) shall be included in the Registration Statement. 
 (iv) Withdrawal in Piggyback Registration.
If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter delivered at least seven (7) days prior to the effective date of the Registration
Statement. Any Registrable Securities or other securities excluded or withdrawn from such underwriting shall be withdrawn from such Registration. 

  
 8 

 (c) Blue Sky in Piggyback Registration. In the event of any Registration of
Registrable Securities pursuant to Section 1.6, the Company will exercise its best efforts to Register and qualify the securities covered by the Registration Statement under such other securities or Blue Sky laws of such jurisdictions as shall
be reasonably appropriate for the distribution of such securities; provided, however, that: 
 (i) the Company shall not be
required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions; and 

(ii) notwithstanding anything in this Agreement to the contrary, in the event any jurisdiction in which the securities shall be
qualified imposes a non-waivable requirement that expenses incurred in connection with the qualification of the securities be borne by selling shareholders, such expenses shall be payable pro rata by selling shareholders. 

1.7 Expenses of Registration. All Registration Expenses incurred in connection with Registrations pursuant to Section 1.5(a),
all registrations pursuant to Section 1.5(c) and all Registrations pursuant to Section 1.6, shall be borne by the Company. Notwithstanding the above, the Company shall not be required to pay for any expenses of any registration proceeding
begun pursuant to Section 1.5 if the registration request is subsequently withdrawn at the request of the Initiating Holders, unless at the time of such withdrawal, the Holders have learned of a Material Adverse Event with respect to the
Company not known to the Holders at the time of their request. All Selling Expenses shall be borne by the holders of the securities registered pro rata on the basis of the number of shares registered. 

1.8 Registration Procedures. Whenever required under this Agreement to effect the Registration of any securities of the Company,
subject to the other provisions of this Agreement, the Company shall, as expeditiously as reasonably possible: 
 (a) Prepare
and file with the Commission a Registration Statement with respect to such securities and use its diligent commercially reasonable efforts to cause such Registration Statement to become and remain effective for up to ninety (90) days or until
the distribution described in the Registration Statement has been completed. 
 (b) Prepare and file with the Commission such
amendments and supplements to such Registration Statement and the prospectus used in connection with such Registration Statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all
securities covered by such Registration Statement. 
 (c) Furnish to the Holders participating in such Registration and to the
underwriters of the securities being Registered such reasonable number of copies of the Registration Statement, preliminary prospectus, and final prospectus as they may request in order to facilitate the public offering of such securities.

 (d) Use its commercially reasonable efforts to register and qualify the securities covered by such Registration Statement
under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders. 
 (e) In
the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the Underwriter’s Representative. Each Holder participating in such underwriting shall also
enter into and perform its obligations under such agreement. 

  
 9 

 (f) Notify each Holder of Registrable Securities covered by such Registration Statement at
any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such Registration Statement, as then in effect, includes an untrue
statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. 

(g) Use its commercially reasonable efforts to list the securities being registered on an internationally-recognized securities
exchange. 
 (h) Deliver promptly to counsel to the Holders and each underwriter, if any, participating in the offering of the
Registrable Securities, copies of all correspondence between the Commission and the Company, its counsel or auditors. 
 1.9
Information Furnished by Holder. It shall be a condition precedent of the Company’s obligations under this Agreement that each Holder of Registrable Securities included in any Registration furnish to the Company such information regarding
such Holder and the distribution proposed by such Holder or Holders as the Company may reasonably request. 
 1.10
Indemnification. 
 (a) Company’s Indemnification of Holders. To the extent permitted by law, the Company will
indemnify each Holder, each of its officers, directors and constituent partners, legal counsel for the Holders, and each person controlling such Holder, with respect to which Registration, qualification or compliance of Registrable Securities has
been effected pursuant to this Agreement, and each underwriter, if any, and each person who controls any underwriter against all claims, losses, damages or liabilities (or actions in respect thereof) to the extent such claims, losses, damages or
liabilities arise out of or are based upon any untrue statement (or alleged untrue statement) of a material fact contained in any prospectus or other document (including any related Registration Statement) incident to any such Registration,
qualification or compliance or are based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or any violation by the Company of any rule or
regulation promulgated under the Securities Act applicable to the Company and relating to action or inaction required of the Company in connection with any such Registration, qualification or compliance; and the Company will reimburse each such
Holder, each of its officers, directors and constituent partners, legal counsel for the Holders, each such underwriter and each person who controls any such Holder or underwriter, for any legal and any other expenses reasonably incurred in
connection with investigating or defending any such claim, loss, damage, liability or action; provided, however, that the indemnity contained in this Section 1.10(a) shall not apply to amounts paid in settlement of any such claim, loss, damage,
liability or action if settlement is effected without the consent of the Company (which consent shall not unreasonably be withheld) and; provided, further, that the Company will not be liable in any such case to the extent that any such claim, loss,
damage, liability or expense arises out of or is based upon any untrue statement or omission based upon written information furnished to the Company by such Holder, underwriter, or controlling person and stated to be for use in connection with the
offering of securities of the Company. 

  
 10 

 (b) Holder’s Indemnification of Company. To the extent permitted by law, each
Holder will, if Registrable Securities held by such Holder are included in the securities as to which such Registration, qualification or compliance is being effected pursuant to this Agreement, indemnify the Company, each of its directors and
officers, each legal counsel and independent accountant of the Company, each underwriter, if any, of the Company’s securities covered by such a Registration Statement, each person who controls the Company or such underwriter within the meaning
of the Securities Act, and each other such Holder, each of its officers, directors and constituent partners and each person controlling such other Holder, against all claims, losses, damages and liabilities (or actions in respect thereof) arising
out of or based upon any untrue statement (or alleged untrue statement) of a material fact contained in any such Registration Statement, prospectus, offering circular or other document, or any omission (or alleged omission) to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading, or any violation by such Holder of any rule or regulation promulgated under the Securities Act applicable to such Holder and relating to action
or inaction required of such Holder in connection with any such Registration, qualification or compliance, and will reimburse the Company, such Holders, such directors, officers, partners, persons, law and accounting firms, underwriters or control
persons for any legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action, in each case to the extent, but only to the extent, that such untrue statement (or
alleged untrue statement) or omission (or alleged omission) is made in such Registration Statement, prospectus, offering circular or other document in reliance upon and in conformity with written information furnished to the Company by such Holder
and stated to be specifically for use in connection with the offering of securities of the Company; provided, however, that each Holder’s liability under this Section 1.10(b) shall not exceed such Holder’s proceeds from the offering
of securities made in connection with such Registration; and provided, further, that the indemnity contained in this Section 1.10(b) shall not apply to amounts paid in settlement of any such claim, loss, damage, liability or action if
settlement is effected without the consent of such Holder (which consent shall not unreasonably be withheld). 
 (c)
Indemnification Procedure. Promptly after receipt by an indemnified party under this Section 1.10 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an
indemnifying party under this Section 1.10, notify the indemnifying party in writing of the commencement thereof and generally summarize such action. The indemnifying party shall have the right to participate in and to assume the defense of
such claim; provided, however, that the indemnifying party shall be entitled to select counsel for the defense of such claim with the approval of any parties entitled to indemnification, which approval shall not be unreasonably withheld; provided,
further, that if either party reasonably determines that there may be a conflict between the position of the Company and the Investors in conducting the defense of such action, suit or proceeding by reason of recognized claims for indemnity under
this Section 1.10, then counsel for such party shall be entitled to conduct the defense to the extent reasonably determined by such counsel to be necessary to protect the interest of such party. The failure to notify an indemnifying party
promptly of the commencement of any such action, if prejudicial to the ability of the indemnifying party to defend such action, shall relieve such indemnifying party, to the extent so prejudiced, of any liability to the indemnified party under this
Section 1.10, but the omission so to notify the indemnifying party will not relieve such party of any liability that such party may have to any indemnified party otherwise other than under this Section 1.10. 

  
 11 

 (d) Contribution. If the indemnification provided for in this Section 1.10 is
held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to herein, then the indemnifying party, in lieu of indemnifying such indemnified party
hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one
hand and the indemnified party on the other hand in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense, as well, as any other relevant equitable considerations; provided, however, that no
contribution by any Holder, when combined with any amounts paid by such Holder pursuant to Section 1.10(b), shall exceed the gross proceeds from the offering received by such Holder. The relative fault of the indemnifying party and the
indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 

(e) Underwriting. Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained
in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Survival. The obligations of the Company and Holders under this Section 1.10 shall survive the completion of any
offering of Registrable Securities in a registration statement under Sections 1.5 or 1.6 and otherwise. 
 1.11
Limitations on Registration Rights Granted to Other Securities. From and after the date of this Agreement, the Company shall not enter into any agreement with any holder or prospective holder of any securities of the Company providing for the
granting to such holder of any information or Registration rights, except that, with the consent of the Holders of a majority of the aggregate of the Registrable Securities then outstanding, additional holders may be added as parties to this
Agreement with regard to any or all securities of the Company held by them. Any such additional parties shall execute a counterpart of this Agreement, and upon execution by such additional parties and by the Company, shall be considered an Investor
for all purposes of this Agreement. The additional parties and the additional Registrable Securities shall be identified in an amendment to Schedule 1 hereto. In no event shall the Company grant registration rights senior to, or
on a parity with, those granted to the Series E Holders, Series F Holders or Series G Holders hereunder without the consent of the Series E Holders, Series F Holders and Series G Holders holding a majority of the Series E
Preference Shares, Series F Preference Shares and Series G Preference Shares, voting together on an as-converted basis. 

  
 12 

 1.12 Transfer of Rights. The rights to information under Sections 1.2 and 1.3
and the right to cause the Company to Register securities granted by the Company to the Investors under this Agreement may be assigned by any Holder to a transferee or assignee of any Convertible Securities or Registrable Securities not sold to the
public acquiring at least 12,500 shares of such Holder’s Registrable Securities (equitably adjusted for any share splits, subdivisions, share dividends, changes, combinations or the like); provided, however, that: 

(a) the Company must receive written notice prior to the time of said transfer, stating the name and address of said transferee or
assignee and identifying the securities with respect to which such information and Registration rights are being assigned; and 

(b) the transferee or assignee of such rights must not be a person deemed by the Board of Directors of the Company, in its best
judgment, to be a competitor or potential competitor of the Company. Notwithstanding the limitation set forth in the foregoing sentence respecting the minimum number of shares which must be transferred, any Holder which is a partnership or an LLC
may transfer such Holder’s Registration rights to such Holder’s constituent partners or members without restriction as to the number or percentage of shares acquired by any such constituent partner or member. 

For the avoidance of doubt, notwithstanding any transfer or assignment as contemplated by this Section 1.12, the transferor or
assignor of any Convertible Securities or Registrable Securities shall retain their own rights to information under Sections 1.2 and 1.3 and the right to cause the Company to register securities granted by the Company to the Investors under
this Agreement following any such transfer or assignment, provided that they retain at least 12,500 shares of Convertible Securities or Registrable Securities. 
 1.13 Market Standoff. Each Holder hereby agrees that, if so requested by the Company and the Underwriter’s Representative (if any) in connection with the Company’s IPO, such Holder shall
not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise transfer or dispose of any Registrable Securities or other securities of the Company without the prior written consent of the Company and the
Underwriter’s Representative for such period of time (not to exceed 180 days) following the effective date of a Registration Statement of the Company filed under the Securities Act (or such other period as may be requested by the Company or the
Underwriter’s Representative to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions
contained in NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto) as may be requested by the Underwriter’s Representative and agreed to by the Company and the Series E Holders or Series F
Holders holding a majority of the Series E Preference Shares and Series F Preference Shares, voting together on as-converted basis, provided that all executive officers and directors of the Company and current holders of at least one
percent of the Company’s voting securities enter into similar agreements, and that if any waivers are granted by the Underwriters’ Representative to such executive officers and directors, similar waivers will be granted to such Holder.

  
 13 

 1.14 No Action Letter or Opinion of Counsel in Lieu of Registration: Conversion of
Preference Shares. Notwithstanding anything else in this Agreement, if the Company shall have obtained from the Commission a “no action” letter in which the Commission has indicated that it will take no action if, without
Registration under the Securities Act, any Holder disposes of Registrable Securities covered by any request for Registration made under this Section 1.14 in the specific manner in which such Holder proposes to dispose of the Registrable
Securities included in such request (such as including, without limitation, inclusion of such Registrable Securities in an underwriting initiated by either the Company or the Holders), or if in the opinion of counsel for the Company concurred in by
counsel for such Holder, which concurrence shall not be unreasonably withheld, no Registration under the Securities Act is required in connection with such disposition, the shares included in such request shall not be eligible for Registration under
this Agreement; provided, however, that any Registrable Securities not so disposed of shall be eligible for Registration in accordance with the terms of this Agreement with respect to other proposed dispositions to which this Section 1.14 does
not apply. The Registration rights of the Holders of the shares set forth in this Agreement are conditioned upon the conversion of the shares with respect to which registration is sought into Ordinary Shares prior to the effective date of the
Registration Statement. 
 1.15 Termination of Registration Rights. The rights to cause the Company to register
securities granted under Sections 1.5 and 1.6 of this Agreement and to receive notices pursuant to Section 1.6 of this Agreement shall terminate, with respect to each Holder, on the earlier of (i) the date five years after the closing
date of the Company’s IPO, and (ii) after the Company’s IPO, upon such Holder holding less than 1% of the outstanding Ordinary Shares of the Company and if such Holder is eligible to sell all of such Holder’s Registrable
Securities under Rule 144 of the Securities Act within any 90-day period without volume limitations, or as otherwise permitted under Rule 144 without restriction. 
 1.16 Grant of Right of First Refusal. 
 (a) Right of First
Refusal of New Securities. The Company hereby grants to each Investor the right of first refusal to purchase up to its “Pro Rata Share” (as defined below) of New Securities (as defined below) which the Company may, from time to time,
propose to sell and issue. Each Investor may purchase said New Securities on the same terms and at the same price at which the Company proposes to sell the New Securities. The “Pro Rata Share” of each Investor, for purposes of this
right of first refusal, is the ratio of (i) the total number of Ordinary Shares held by such Investor (including any Ordinary Shares into which shares of the Convertible Securities held by such Investor are convertible) to (ii) the total
number of Ordinary Shares outstanding (including any Ordinary Shares into which all Convertible Securities, warrants, rights and options outstanding immediately prior to the issuance of the New Securities are convertible or exercisable). 

(b) New Securities. “New Securities” shall mean any offering by the Company of any Ordinary Shares or Preference
Shares of the Company, whether now authorized or not, and rights, options, or warrants to purchase Ordinary Shares or Preference Shares, and securities of any type whatsoever that are, or may become, convertible into said Ordinary Shares or
Preference Shares; provided, however, that “New Securities” does not include: (i) securities issuable upon conversion of any outstanding Preference Shares and Notes; (ii) securities offered to the public pursuant to a
Registration Statement filed under the Securities Act; (iii) securities issued pursuant to the acquisition of another corporation by the Company by merger, purchase of substantially all of the assets, or other reorganization whereby the Company
owns not less than fifty-one percent (51%) of the voting power of such corporation, including for the avoidance of doubt, securities issuable to Dunsmore International Ltd. or its assigns pursuant to the Business Acquisition Agreement dated
June 30, 2007; (iv) the Company’s Ordinary Shares (or related options) issued or issuable at any time to employees, directors or consultants of the Company, or any subsidiary, pursuant to any employee share offering, plan, or
arrangement approved by the Board of Directors; (v) the Company’s Ordinary Shares or Preference Shares issued in connection with any share split, share dividend, or recapitalization by the Company; (vi) Series D Preferred Shares
issued pursuant to the Company’s Mirror 2004 Special Purpose Stock Option Plan and the Ordinary Shares upon conversion thereof; and (vii) Ordinary Shares or Preference Shares (or related options or warrants) issued in connection with:
(1) strategic transactions involving the Company and other entities, including: (A) joint ventures, manufacturing, marketing or distribution arrangements; or (B) technology transfer or development arrangements; or (2) equipment
lease transactions; provided, that such strategic or equipment lease transactions and the issuance of shares therein, have been approved by the Company’s Board of Directors. 

  
 14 

 (c) Notice. In the event the Company proposes to undertake an issuance of New
Securities, it shall give to each Investor written notice (the “Notice”) of its intention, describing the type of New Securities, the price, the terms upon which the Company proposes to issue the same, the number of shares which
such Investor is entitled to purchase pursuant to Section 1.16(a), and a statement that each Investor shall have 20 days to respond to such Notice. Each Investor shall have 20 days from the date of receipt of the Notice to agree to purchase any
or all of its Pro Rata Share of the New Securities for the price and upon the terms specified in the Notice by giving written notice to the Company and stating therein the quantity of New Securities to be purchased and forwarding payment for such
New Securities to the Company if immediate payment is required by such terms. 
 (d) Sale of New Securities. In the
event an Investor fails to exercise in full its right of first refusal within such 20 day period, the Company shall have 90 days thereafter to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be
closed, if at all, within 60 days after the date of such agreement) to sell the New Securities respecting which such Investor’s rights were not exercised, at a price and upon general terms no more favorable to the purchaser thereof than
specified in the Notice. In the event the Company has not sold the New Securities within such 90 day period (or sold and issued New Securities in accordance with the foregoing within 60 days from the date of such agreement), the Company shall not
thereafter issue or sell any New Securities without first offering such securities to such Investor in the manner provided above. 
 (e) Termination of Right of First Refusal. The covenants of the Company set forth in this Section 1.16 shall be terminated and be of no further force or effect upon the earlier of
(a) immediately prior to the closing of the Company’s IPO and (b) the date the Company registers any securities under the Exchange Act, and such covenants shall terminate as to any Investor as of the date such Investor no longer holds
any shares of the capital share of the Company. 

  
 15 

 2. RIGHT OF FIRST REFUSAL AND CO-SALE 

2.1 Senior Investor Right of First Refusal; Senior Investor Co-Sale Right. 

(a) Senior Investor Right of First Refusal. If an Investor proposes to sell, pledge, or otherwise transfer any of the
Company’s Preference Shares now owned or subsequently acquired by such Investor or any interest therein (the “Investor Sale Shares,” and such Investor, the “Selling Investor”) to any person or entity, then
holders of Series E Shares, Series F Shares and Series G Shares (each a “Senior Investor,” and collectively, the “Senior Investors”) shall have a right of first refusal (the “Senior Investor ROFR”)
to purchase some or all of the Investor Sale Shares. The Selling Investor shall give a written notice to the Company and the Senior Investors describing fully the proposed transfer including the number of Investor Sale Shares, the proposed transfer
price, the name and address of the proposed transferee (the “ROFR Notice”). The ROFR Notice shall be signed both by the Selling Investor and by the proposed transferee and must constitute a binding commitment of both such parties
for the transfer of the Investor Sale Shares. Each Senior Investor shall have 20 business days after the date the ROFR Notice is delivered in which to purchase up to its Senior Investor Pro Rata Share (as defined below) of the Investor Sale Shares
subject to the ROFR Notice on the same terms and conditions as set forth therein. The Senior Investors shall exercise this right by delivery of a notice of exercise (the “ROFR Exercise Notice”) to the Selling Investor within 20
business days after the date the ROFR Notice is delivered. The ROFR Exercise Notice shall indicate the number of Investor Sale Shares (which may be some or all of a Senior Investor’s Senior Investor Pro Rata Share) the Senior Investors wish to
purchase pursuant to this Senior Investor ROFR. To the extent the Senior Investors exercise their Senior Investor ROFR in accordance with the terms and conditions set forth herein, the number of Investor Sale Shares that the Selling Investor may
sell to the proposed transferee in the transaction shall be correspondingly reduced. In the event of any Senior Investor not exercising its Senior Investor ROFR in respect of all of its Senior Investor Pro Rata Share of the Investor Sale Shares, the
Investor Sale Shares not purchased by such Senior Investor shall be offered by the Selling Investor proportionately to the other Senior Investors who have exercised their respective Senior Investor ROFR in full (and who have indicated in their ROFR
Exercise Notice their willingness to purchase any unaccepted Investor Sale Shares) and such offer shall specify a period of 20 business days within which such offer if not accepted will be deemed declined. For purposes of this Section 2.1(a), a
Senior Investor’s “Senior Investor Pro Rata Share” shall be that proportion that the number of Ordinary Shares issued or issuable upon conversion of the Preference Shares held by such Senior Investor bears to the total number
of Ordinary Shares issued or issuable upon conversion of the Preference Shares held by all Senior Investors (excluding the Preference Shares held by the Selling Investor, if the Selling Investor is a Senior Investor). 

(b) Senior Investor Co-Sale Right. 
 (i) Selling Shareholder. Without prejudice to Section 2.1(a), each Senior Investor shall also have the right, exercisable upon written notice (the “Co-Sale Exercise Notice”)
to the Selling Investor within 20 business days after the date the ROFR Notice is delivered, to participate in the sale of the Investor Sale Shares on the same terms and conditions as such Selling Investor (the “Senior Investor Co-Sale
Right”). Each Senior Investor exercising the Senior Investor Co-Sale Right shall indicate the number of Series E Preference Shares, Series F Preference Shares and/or Series G Preference Shares, as applicable, such Senior Investor wishes to
sell. Each Senior Investor may elect to sell to the proposed transferee (or, upon the unwillingness of any proposed transferee to purchase directly from the Senior Investor, to the Selling Investor) shares of Series E Preference Shares,
Series F Preference Shares or Series G Preference Shares equal to all or some of such Senior Investor’s Senior Investor Co-Sale Pro Rata Share (as defined below) of the number of the Investor Sale Shares. To the extent the Senior Investors
exercise their Senior Investor Co-Sale Right in accordance with the terms and conditions set forth herein, the number of Investor Sale Shares that the Selling Investor may sell in the transaction shall be correspondingly reduced. In the event of any
Senior Investor not exercising its Senior Investor Co-Sale Right in full (the “Unused Allocation”), the Selling Investor shall by notice in writing notify the other Senior Investors who have exercised their respective Senior
Investor Co-Sale Rights in full (and who have indicated in their Co-Sale Exercise Notice their desire to sell additional number of shares of Series E Preference Shares, Series F Preference Shares or Series G Preference Shares) and such
investors shall have the right, within a period of 20 business days after the date the ROFR Notice is delivered, to sell to the proposed transferee (or, upon the unwillingness of any proposed transferee to purchase directly from the Senior Investor,
to the Selling Investor) such number of additional shares of Series E Preference Shares, Series F Preference Shares or Series G Preference Shares which is equal to its proportionate share of the Series E Preference Shares,
Series F Preference Shares or Series G Preference Shares comprised in the Unused Allocation. 

  
 16 

 (ii) Senior Investor Co-Sale Pro Rata Share. For purposes of Section 2.1(b),
each Senior Investor’s “Senior Investor Co-Sale Pro Rata Share” shall be determined as of the date the Co-Sale Exercise Notice is delivered to the Company and shall be that proportion that the number of Ordinary Shares issued
or issuable upon conversion of the Series E Preference Shares, Series F Preference Shares or Series G Preference Shares held by such Senior Investor bears to the sum of (x) the total number of Ordinary Shares issued or issuable upon
conversion of the Series E Preference Shares, Series F Preference Shares or Series G Preference Shares held by all Senior Investors plus (y) the total number of Ordinary Shares issued or issuable upon conversion of the Preference
Shares held by the Selling Investor. 
 (iii) Delivery of Certificates. The Senior Investors shall effect their
participation in the sale by promptly delivering to the Selling Investor for transfer to the prospective purchaser one or more certificates, properly endorsed for transfer, which represent the number of Series E Preference Shares, Series F
Preference Shares or Series G Preference Shares which the Senior Investors elect to sell. 
 (iv) Sales Proceeds. The
share certificate or certificates that the Senior Investors deliver to the Selling Investor pursuant to Section 2.1(b)(iii) shall be transferred to the prospective purchaser in consummation of the sale of the Investor Sale Shares pursuant to
the terms and conditions specified in the ROFR Notice, and the Selling Investor shall concurrently therewith remit to the Senior Investors that portion of the sale proceeds to which the Senior Investors are entitled by reason of their participation
in such sale. To the extent that any prospective purchaser or purchasers prohibits such assignment or otherwise refuses to purchase shares or other securities from the Senior Investors hereunder, the Selling Investor shall not sell to such
prospective purchaser or purchasers any Investor Sale Shares unless and until, simultaneously with such sale, the Selling Investor shall purchase such shares or other securities from the Senior Investors. 

  
 17 

 (v) Sale by the Selling Investor. If the Senior Investors do not exercise their
Senior Investor ROFR with respect to the sale of all of the Investor Sale Shares and their Senior Investor Co-Sale Rights with respect to all the Investor Sale Shares, the Selling Investor may, not later than 90 days following delivery to the
Company of the ROFR Notice, conclude a transfer of all such remaining Investor Sale Shares on terms and conditions not more favorable to the transferee than those described in the ROFR Notice. Any proposed transfer on terms and conditions more
favorable than those described in the ROFR Notice, as well as any subsequent proposed transfer of any of the Investor Sale Shares by the Selling Investor, shall again be subject to the Senior Investor ROFR and Senior Investor Co-Sale Right of the
Senior Investors and shall require compliance by such Selling Investor with the procedures described in this Section 2.1. The provisions of this Section 2.1 shall not apply to the sale of shares to be sold in the IPO. 

2.2 Prohibited and Permitted Transfers. 
 (a) Prohibited Transfer. In the event a Selling Investor attempts to sell any Preference Shares in contravention of the Senior Investor ROFR and/or the Senior Investor Co-Sale Right of the Senior
Investors under this Agreement, the Company may issue appropriate “stop-transfer” instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to the same effect in
its own records. Any attempt by the Selling Investor to transfer Preference Shares in violation of Section 2.1 hereof shall be void and the Company agrees it will not effect such a transfer nor will it treat any alleged transferee as the holder
of such shares without the written consent of the Senior Investors. 
 (b) Permitted Transfers. The Senior Investor ROFR
and/or Senior Investor Co-Sale Right of a Senior Investor shall not apply to a proposed transfer of Preference Shares or Ordinary Shares as applicable to (i) one of its Affiliates (as defined below), (ii) partners or members (or retired
partners or retired members) if such holder is a partnership or a limited liability company, as the case may be, (iii) in the case of such holder being constituted as a fund, any other entity managed by the same fund manager, (iv) in the
case of an entity, in connection with the dissolution or winding up of the entity, provided that the proposed transfer is not to more than two (2) persons or entities, (v) in the case of an individual, in connection with any transfers to a
spouse, ex-spouse, domestic partner, lineal descendant or antecedent, brother or sister, the adopted child or adopted grandchild, or the spouse or domestic partner of any child, adopted child, grandchild or adopted grandchild, or to a trust or
trusts for the exclusive benefit of the Selling Investor or those members of Seller’s family specified in this clause (v) or transfers by devise or descent; provided that, in all cases in clauses (i) through (v), the transferee
or other recipient executes a counterpart copy of this Agreement and becomes bound thereby as was the Selling Investor or (vi) in the Company’s IPO. “Affiliate” means any person that directly, or indirectly through one or
more intermediaries, controls, or is controlled by or is under common control with the person specified and, for this purpose, a person shall be treated as being controlled by another person if that other person is able to direct its affairs and/or
to control the composition of its board of directors or equivalent body. The Senior Investor ROFR and the Senior Investor Co-Sale Right shall also not apply to a pledge of Shares by any Selling Investor that creates a mere security interest,
provided the pledgee agrees to be bound by the terms of this Agreement. 

  
 18 

 2.3 Legend; Stop Transfer Instructions. 

(a) Legend. Each certificate representing Preference Shares now or hereafter owned by any Investor or issued to any person in
connection with a transfer pursuant to Section 2.2 hereof shall be endorsed with the following legends: 
 THE SALE,
PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES, REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN INVESTORS’ RIGHTS AGREEMENT BY AND AMONG THE HOLDER HEREOF, THE COMPANY AND CERTAIN HOLDERS OF SHARE
CAPITAL OF THE COMPANY, AS MAY BE AMENDED AND RESTATED FROM TIME TO TIME. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 
 (b) Stop Transfer Instructions. The Selling Investors and Senior Investors agree that the Company may instruct its transfer agent to impose transfer restrictions on the shares represented by
certificates bearing the legend referred to in Section 2.3(a) above to enforce the provisions of this Agreement and the Company agrees promptly to do so. The legend shall be removed upon termination of this Agreement. 

(c) Company Records. The Company shall not transfer on its register of members any of the shares held by any Selling Investor
without first ascertaining compliance with all of the applicable provisions of this Agreement with respect to such transfer 

2.4 Term and Termination. This Section 2 shall terminate upon the earlier of: (i) the Company’s IPO; or (ii) a
Merger. 
 3. CO-SALE 
 3.1 Right of Co-Sale. 
 (a) Right of Co-Sale. If any holder of
Ordinary Shares who hold more than 50,000 Ordinary Shares of the Company (each a “Selling Ordinary Holder”) proposes to sell, pledge, or otherwise transfer any Ordinary Shares currently owned or hereafter acquired (the “Sale
Shares”) or any interest therein to any person or entity for value, the Investors shall each have the right of co-sale (the “Right of Co-Sale”) with respect to such Sale Shares as more fully described herein. The Selling
Ordinary Holder shall give a written notice (the “Transfer Notice”) to the Company, and contemporaneously to the Investors at each such Investor’s address as shown on the Company’s register of members, describing fully the
proposed transfer, including the number of Sale Shares, the proposed transfer price, and the name and address of the proposed transferee (the “Proposed Transferee”). The Transfer Notice shall be signed both by the Selling Ordinary
Holder and by the Proposed Transferee and must constitute a binding commitment of both such parties for the transfer of the Sale Shares. Within 20 business days after receipt of the Transfer Notice, each Investor will have a right to sell such
number of Shares equal to its pro rata share of the Sale Shares (the “Co-Sale Pro Rata Share”) on the same terms as the Selling Ordinary Holder. 

  
 19 

 (b) Co-Sale Pro Rata Share. Each Investor’s Co-Sale Pro Rata Share shall be
determined as of the date the Transfer Notice is delivered to the Company and shall be that proportion which the number of shares held by such Investor bears to the sum of (x) the total number of shares on an as-converted basis held by all
Investors plus (y) the total number of Ordinary Shares held by the Selling Ordinary Holder. 
 (c) Mechanics of
Sale. 
 (i) Exercise by Investor. Each Investor shall exercise its Right of Co-Sale by delivering a notice of
exercise to the Selling Ordinary Holder (with a copy to the Company) (the “Exercise Notice”) within 20 business days after the date the Transfer Notice has been delivered by such Selling Ordinary Holder to the Company and the
Investors. 
 (ii) An Investor exercising its Right of Co-Sale shall deliver to the Selling Ordinary Shareholder at or before
the closing, one or more certificates, properly endorsed for transfer, representing a number of Ordinary Shares not to exceed the number of Ordinary Shares to which such Investor is entitled, representing such Ordinary Shares to be transferred by
the Selling Ordinary Shareholder on behalf of the Investor. If an Investor exercising its Right of Co-Sale does not hold Ordinary Shares, then the Company shall, in accordance with the conversion provision and other relevant provisions of the
Company’s then effective Memorandum of Association and Articles of Association, promptly effect any necessary conversion and issue a certificate representing the proper number of Ordinary Shares to be sold pursuant to this Right of Co-Sale.
Following the closing, the Company shall deliver a certificate for the remaining balance of the securities held by the Investor exercising its Right of Co-Sale, if any, to such Investor. At the closing, such certificates or other instruments will be
transferred and delivered to the Proposed Transferee as set forth in the Transfer Notice in consummation of the transfer of the Sale Shares pursuant to the terms and conditions specified in the Transfer Notice, and the Selling Ordinary Holder will
remit, or will cause to be remitted, to each selling Investor, within ten (10) days after such closing, that portion of the proceeds of the transfer to which each selling Investor is entitled by reason of each selling Investor’s
participation in such transfer pursuant to the Right of Co-Sale. 
 (iii) Further allocation. To the extent the
Investors exercise their Right of Co-Sale in accordance with the terms and conditions set forth herein, the number of Sale Shares that the Selling Ordinary Holder may sell in the transaction shall be correspondingly reduced. In the event of any
Investor not exercising its Right of Co-Sale in full (the “Co-Sale Unused Allocation”), the Selling Ordinary Holder shall by notice in writing notify the other Investors who have exercised their respective Right of Co-Sale in full
(and who have indicated in their Exercise Notice their desire to sell additional number of shares) and such Investors shall have the right, within a period of 20 business days from such notice, to sell to the Proposed Transferee (or, upon the
unwillingness of any Proposed Transferee to purchase directly from the Investor, to the Selling Ordinary Holder) such number of additional shares which equal to its proportionate share of the Sale Shares comprised in the Co-Sale Unused Allocation.

  
 20 

 (iv) Assignment of Interest. The Selling Ordinary Holder shall assign to each
Investor who exercises its Right of Co-Sale as much of its interest in the agreement of sale with the Proposed Transferee or Transferees as such Investor shall be entitled to and shall accept. To the extent that any Proposed Transferee prohibits
such assignment or otherwise refuses to purchase shares or other securities from such Investor, the Selling Ordinary Holder shall not sell to such Proposed Transferee any Sale Shares unless and until, simultaneously with such sale, such Selling
Ordinary Holder shall purchase such shares or other securities from such Investor for the same consideration and on the same terms and conditions as the proposed transfer described in the Transfer Notice. 

(v) Failure to Exercise Right of Co-Sale; Additional Transfers. If the Investors do not exercise their respective Right of
Co-Sale, the Selling Ordinary Holder may, not later than 90 days following delivery to the Company of the Transfer Notice, conclude a transfer of not less than all of the Sale Shares covered by the Transfer Notice (with respect to which the
Investors have not elected to exercise their Co-Sale Rights) on terms and conditions not more favorable to the transferee than those described in the Transfer Notice. Any proposed transfer of more Sale Shares by the Selling Ordinary Holder shall
again be subject to the Right of Co-Sale and shall require compliance by such Selling Ordinary Holder with the procedures described in this Section 3.1. The non-exercise or partial exercise of the rights of any Investor hereunder to participate
in one or more sales of Sale Shares made by a Selling Ordinary Holder shall not adversely affect such Investor’s right to participate in subsequent sales of Sale Shares by a Selling Ordinary Holder. 

(vi) Company Records. The Company shall not transfer on its books any of the Ordinary Shares held by any Selling Ordinary Holder
without first ascertaining compliance with all of the applicable provisions of this Agreement with respect to such transfer. 

(d) Exceptions to Right of Co-Sale. The Right of Co-Sale shall not apply to a permitted transfer pursuant to Section 2.2
(b) or a pledge of shares by any Selling Ordinary Holder that creates a mere security interest, provided the pledgee agrees to be bound by the terms of this Agreement. 
 (e) Stop-Transfer Orders. Each Selling Ordinary Holder agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue appropriate
“stop-transfer” instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records. The provisions of this Section 3.1 shall not
apply to the sale of shares in the IPO. 
 3.2 Term and Termination. This Section 3 shall terminate upon the earlier
of: (i) the Company’s IPO; or (ii) a Merger. 
 3.3 Legend-Requirement. All certificates evidencing the
shares subject to this Section 3 shall, during the term of this Agreement, bear such restrictive legends as the Company and the Company’s counsel deem necessary or advisable under applicable law or pursuant to this Agreement, including
without limitation the following: 
 THE SECURITIES REPRESENTED HEREBY ARE SUBJECT TO A RIGHT OF CO-SALE BY CERTAIN SHAREHOLDERS
OF THE COMPANY, PURSUANT TO AN AGREEMENT RELATING TO SUCH SECURITIES, AS AMENDED AND RESTATED FROM TIME TO TIME, AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE TERMS OF SUCH AGREEMENT. 

  
 21 

 4. VOTING 
 4.1 Share Capital. The Shareholders expressly agree that the terms and restrictions of this Agreement shall apply to all share capital (including, but without limitation, all classes of ordinary,
preference, voting and nonvoting share capital) of the Company which any of them now owns or hereafter acquires by any means, including without limitation by purchase, assignment, conversion of Convertible Securities or operation of law, or as a
result of any share dividend, share split, reorganization, reclassification, whether voluntary or involuntary, or other similar transaction, and to any share capital of any successor in interest of the Company, whether by sale, merger, amalgamation,
scheme of arrangement, consolidation or other similar transaction, or by purchase, assignment or operation of law (the “Company Shares”). 
 4.2 Election of Board of Directors. 
 (a) Size of Board of
Directors. During the term of this Agreement, each Shareholder, in his/her/its capacity as a shareholder, agrees to vote all Company Shares now or hereafter directly or indirectly owned (of record or beneficially) by such Shareholder to maintain
the authorized number of members of the Board of Directors of the Company at nine (9) directors, and to oppose any effort by any party to change the authorized number of directors of the Company from nine (9) directors. 

(b) Voting; Board Composition. Subject to the rights of the shareholders of the Company to remove a director for cause in
accordance with applicable law, during the term of this Agreement, each Shareholder agrees to vote (or consent pursuant to an action by written consent of the shareholders of the Company) all Company Shares now or hereafter directly or indirectly
owned of record or beneficially by such Shareholder, or to cause such Company Shares to be voted, in such manner as may be necessary to elect (and maintain in office) as members of the Company’s Board of Directors (the
“Board”), the following nine (9) individuals in accordance with the voting provisions of the Company’s Amended and Restated Articles of Association, as the same shall be amended, or amended and restated, hereafter (the
“Restated Articles”): 
 (i) One (1) individual who, at the time in question, is the Company’s Chief
Executive Officer (the “CEO Designee”); 
 (ii) One (1) individual who, at the time in question, is the
Company’s Secretary (the “Secretary Designee”); 
 (iii) One (1) individual designated from time to
time in a writing delivered to the Company and signed by Shareholders who, at the time in question, hold Series A Preference Shares, Series B Preference Shares and Series C Preference Shares of the Company representing at least a
majority of the voting power of all issued and outstanding Series A Preference Shares, Series B Preference Shares and Series C Preference Shares of the Company, voting together on an as-converted basis, then held by all Shareholders (the
“Series A, B and C Designee”); 

  
 22 

 (iv) One (1) individual designated from time to time in a writing delivered to the
Company and signed by Shareholders who, at the time in question, hold Series D Preference Shares of the Company representing at least a majority of the voting power of all issued and outstanding Series D Preference Shares of the Company,
voting as a separate series, then held by all Shareholders (the “Series D Designees”); 
 (v) One
(1) individual designated from time to time in a writing delivered to the Company and signed by Shareholders who, at the time in question, hold Series E Preference Shares of the Company representing at least a majority of the voting power
of all issued and outstanding Series E Preference Shares of the Company, voting as a separate series, then held by all Shareholders (the “Series E Designees”); 

(vi) Two (2) individuals designated from time to time in a writing delivered to the Company and signed by Shareholders who, at the
time in question, hold Series F Preference Shares of the Company representing at least a majority of the voting power of all issued and outstanding Series F Preference Shares of the Company, voting as a separate series, then held by all
Shareholders (the “Series F Designees”); 
 (vii) One (1) individual, who shall be an independent
director, designated from time to time in a writing delivered to the Company and signed by Shareholders who, at the time in question, hold shares of issued and outstanding Ordinary Shares of the Company representing at least a majority of the voting
power of all issued and outstanding Ordinary Shares of the Company then held by all Shareholders (the “Shareholders’ Designee”); and 
 (viii) One (1) individual, for so long as Capinfo (Hong Kong) Company Limited (“CapInfo HK”) owns at least 7,137,500 Ordinary Shares (as adjusted for combinations, consolidations,
subdivisions, or share splits with respect to such shares), designated by CapInfo HK (the “CapInfo Designee”). 
 For purposes of this Agreement: (i) any individual who is designated for election to the Board pursuant to the foregoing provisions of this Section 4.2(b) is referred to below as a
“Board Designee;” and (ii) any individual, entity, or group of individuals and/or entities who has the right to designate one (1) or more Board Designees for election to the Board pursuant to the foregoing provisions of
this Section 4.2(b) is referred to below as a “Designator” or as “Designators,” as applicable. 
 (c) Initial Board Members. The CEO Designee shall be Frederick Sum; the Secretary Designee shall be Deborah Wang; the Series A, B and C Designee shall be Abraham Jou; the Series D
Designee shall be David Wang; the Series E Designee shall be Max Fang; the initial Series F Designees shall be Philip Pearson and John Small; the Shareholders’ Designee shall be Charles Skibo and the CapInfo Designee shall be Xinxiang
Chen. 

  
 23 

 (d) Changes in Board Designees. From time to time during the term of this Agreement,
a Designator or Designators may, in their sole discretion: 
 (i) elect to remove from the Board any incumbent Board Designee
who occupies a Board seat for which such Designator or Designators are entitled to designate the Board Designee under Section 4.2(b); and/or 
 (ii) designate a new Board Designee for election to a Board seat for which such Designator or Designators are entitled to designate the Board Designee under Section 4.2(b) (whether to replace a prior
Board Designee or to fill a vacancy in such Board seat); 
 provided such removal and/or designation of a Board Designee
is approved in a writing signed by Designators who are entitled to designate such Board Designee under Section 4.2(b), in which case such election to remove a Board Designee and/or elect a new Board Designee will be binding on all such
Designators. In the event of such a removal and/or designation of a Board Designee under this Section 4.2(d), the Shareholders shall vote their Company Shares as provided in Section 4.2(b), to cause: (a) the removal from the Board of
the Board Designee or Designees so designated for removal by the appropriate Designators or Designators; and (b) the election to the Board of any new Board Designee or Designees so designated for election to the Board by the appropriate
Designator or Designators. 
 (e) Notice; Covenant to Vote in Accord. The Company shall promptly give each of the
Shareholders written notice of any change in composition of the Board and of any proposal by a Designator or Designators to remove or elect a new Board Designee as described in this Section 4.2 above. In any election of directors pursuant to
this Section 4.2, the Shareholders shall vote their Company Shares in a manner sufficient to elect to the Board the individuals to be elected thereto as provided in this Section 4.2. 

4.3 Further Assurances; Enforcement. Each of the Shareholders and the Company agree not to vote any Company Shares, or to take any
other actions, that would in any manner defeat, impair, be inconsistent with or adversely affect the stated intentions of the parties under Section 4.2; provided, however, that the Company shall have no obligation to enforce any
right among the Shareholders in this Agreement, to arbitrate any dispute or to reject any vote of any party otherwise in accordance with applicable corporate law, absent a court order to do so. 

4.4 Transferees; Legends on Certificates. 
 (a) Effect on Transferees. Each and every transferee or assignee of any Company Shares from any Shareholder shall be bound by and subject to the terms and conditions of this Agreement that are
applicable to the transferor or assignor of such Company Shares, and the Company shall require, as a condition precedent to the transfer of any Company Shares subject to this Agreement, that the transferee agrees in writing to be bound by, and
subject to, all the terms and conditions of this Agreement. 

  
 24 

 (b) Legend. The Shareholders agree that all Company share certificates now or
hereafter held by them that represent Company Shares subject to this Agreement will be stamped or otherwise imprinted with a legend to read as follows 
 THE SHARES EVIDENCED BY THIS CERTIFICATE ARE SUBJECT TO AGREEMENTS AND RESTRICTIONS WITH REGARD TO THE VOTING OF SUCH SHARES AND THEIR TRANSFER, AS PROVIDED IN THE PROVISIONS OF AN INVESTORS’ RIGHTS
AGREEMENT, AS MAY BE AMENDED AND RESTATED FROM TIME TO TIME, A COPY OF WHICH IS ON FILE IN THE OFFICE OF THE SECRETARY OF THE COMPANY. 
 4.5 Enforcement of Agreement. Each of the Shareholders acknowledges and agrees that any breach by any of them of this Agreement shall cause the other Shareholders irreparable harm which may not be
adequately compensable by money damages. Accordingly, in the event of a breach or threatened breach by a Shareholder of any provision of this Agreement, the Company and each other Shareholder shall each be entitled to seek the remedies of specific
performance, injunction or other preliminary or equitable relief, including the right to compel any such breaching Shareholder, as appropriate, to vote such Shareholder’s Company Shares in accordance with the provisions of this Agreement,
without having to prove irreparable harm or actual damages. The foregoing right shall be in addition to such other rights or remedies as may be available to the Company or any Shareholder for any such breach or threatened breach, including but not
limited to the recovery of money damages. 
 4.6 Term. This Section 4 shall terminate upon the earlier of:
(i) the Company’s IPO; or (ii) a Merger. 
 5. MISCELLANEOUS. 

5.1 Drag Along Rights. If a person or entity (the “Offeror”) offers to purchase all of the
Company’s outstanding shares in any Acquisition Transaction (as defined in Article 124 of the Restated Articles) or Sale of Assets (as defined in Article 124 of the Restated Articles) and Shareholders holding at least (i) a majority
of the aggregate number of the Company’s outstanding Ordinary Shares and (ii) a majority of the aggregate number of the Company’s outstanding Preference Shares, with such Preference Shares voting together on as-converted basis
and not as a separate series, (the “Accepting Shareholders”) accept such offer, the Accepting Shareholders are entitled to give all (but not less than all) of the remaining shareholders (“Remaining
Shareholders”) a written notice (“Drag-Along Notice”) and require each Remaining Shareholder to sell to the Offeror all of the Ordinary Share and/or Preference Shares held by each such Remaining Shareholder at the same
price and on the same terms and conditions specified in the Drag-Along Notice. The Drag-Along Notice shall specify (i) the identity of the Offeror; (ii) the price payable for each class or series of the Company’s shares;
and (iii) all other material terms and conditions of the offer made by the Offeror. Such Drag-Along Notices shall be delivered by the Accepting Shareholders to the Company to the attention of the Company’s Chief Executive Officer and
General Counsel, and the Company shall thereupon cause such notices to be transmitted to each Remaining Shareholders at its registered address maintained with the Company. Charges for such transmittal shall be against the account of the Accepting
Shareholders, who will be required to indicate the method of transmission to be used by the Company in this regard (e.g., regular post, express courier, etc.). The Company may require advance payment of funds from the Accepting Shareholders to
cover the costs of transmitting such notices. In furtherance of a sale of the shares of the Company pursuant to this Section 5.1 and Article 31 of the Restated Articles, the Company is authorized to sell the Ordinary Shares and/or Preference
Shares held by the Remaining Shareholders on behalf of the Remaining Shareholders, and pursuant to such authorization, may execute all documents necessary to effectuate the sale and transfer of such shares on behalf of the Remaining Shareholders.
Notwithstanding the foregoing provisions of this Section 5.1, the Remaining Shareholders shall not be obligated to sell their Ordinary Shares and/or Preference Shares, and the Company shall not be authorized to sell the Ordinary Shares and/or
Preference Shares held by the Remaining Shareholders in accordance with the preceding sentence, if the Accepting Shareholders do not complete the sale of all of their Ordinary Shares and/or Preference Shares to the Offeror on the same terms and
conditions specified in the Drag-Along Notice. This Section 5.1 shall terminate upon the earlier of: (i) the Company’s IPO; or (ii) a Merger. 

  
 25 

 5.2 Ownership. Each Investor represents and warrants that such Investor is the sole
legal and beneficial owner of the shares or Notes, as applicable, subject to this Agreement and that no other person has any interest (other than a community property interest) in such shares or Notes, as applicable. 

5.3 Adjustments. This Agreement, and the rights and obligations of the parties hereunder, shall be interpreted insofar as
practicable to account for any share combination, share dividend, share split, recapitalization, or other similar transaction occurring after the Effective Date. 
 5.4 Entire Agreement; Successors and Assigns; Third Parties. This Agreement constitutes the entire contract between the Company and the Investors relative to the subject matters hereof. Any
previous agreement between the Company and the Investors concerning the subject matters hereof is superseded by this Agreement. Subject to the exceptions specifically set forth in this Agreement, the terms and conditions of this Agreement shall
inure to the benefit of and be binding upon the respective executors, administrators, heirs, successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any person, other than the parties hereto
and their successors and assigns, any rights or remedies under or b reason of this Agreement. 
 5.5 Severability. In the
event one or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement,
and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. 

5.6 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California
applicable to contracts entered into and wholly to be performed within the State of California by California residents. 

5.7 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. In order for any person or entity to be entitled to receive the benefits afforded hereunder, or be obligated by the covenants hereunder, such person or entity must have signed
and delivered to the Company a counterpart signature page to this Agreement. 

  
 26 

 5.8 Further Assurance. Each Shareholder undertakes to the other to execute or procure
to be executed all such documents and to do or procure to be done all such other acts and things as may be reasonable and necessary to give all Shareholders the full benefit of this Agreement. 

5.9 Headings. The headings of the Sections of this Agreement are for convenience and shall not by themselves determine the
interpretation of this Agreement. 
 5.10 Notices. Expect as expressly provided herein, any notice required or permitted
hereunder shall be given in writing and shall be conclusively deemed effectively given (i) if delivered by hand, messenger or courier service, when delivered (or if sent via an internationally-recognized overnight courier service, freight
prepaid, specifying next-business-day delivery, one business day after deposit with the courier), or (ii) if sent via mail, at the earlier of its receipt or five days after properly addressing, pre-paying and posting a letter containing the
notice, or (iii) if sent via facsimile, upon confirmation of facsimile transfer or, if sent via electronic mail, upon transmission when directed to the relevant electronic mail address, if sent during normal business hours of the recipient, or
if not sent during normal business hours of the recipient, then on the recipient’s next business day, addressed (i) if to the Company, as set forth below the Company’s name on the signature page of this Agreement, (ii) if to an
Investor, at the Company’s record address for such an Investor, or at such other address as the Company, or such Investor may designate by 10 days’ advance written notice to the other parties hereto. 

5.11 Amendment of Agreement. 
 (a) Subject to Sections 1.11, any provision of Section 1 of this Agreement and this Section 5.11(a) of this Agreement may be amended and the observance thereof may be waived (either
generally or in a particular instance and either retroactively or prospectively) only by a written instrument signed by the Company and by persons holding a majority of the Registrable Securities held by the Investors. 

(b) Any provision of Section 2 of this Agreement and this Section 5.11(b) of the Agreement may be amended and the observance
thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only by the written consent of (i) the Company and (ii) the Investors holding at least a majority of all the Preference Shares
then held by all Investors. 
 (c) Any provision of Section 3 of this Agreement and this Section 5.11(c) of this
Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only by the written consent of (i) the Company, (ii) the Investors holding at least
a majority of Preference Shares and Ordinary Shares held by all Investors, voting on an as-converted basis, and (iii) the holders of Ordinary Shares holding at least a majority of all Ordinary Shares and Preference Shares held by all holders of
Ordinary Shares, voting on an as-converted basis. 

  
 27 

 (d) Any provision of Section 4 of this Agreement and this Section 5.11(d) of this
Agreement may be amended only by a written agreement executed by (i) the Company, (ii) the holders of Series E Preference Shares, Series F Preference Shares and Series G Preference Shares holding at least a majority of the issued and
outstanding Preference Shares on an as-converted basis held by all such holders, and (iii) the Shareholders of at least a majority of the Company’s outstanding capital share on an as-converted basis held by the Shareholders. Any amendment
effected in accordance with this section will be binding upon all parties hereto and each of their respective successors and assigns. No delay or failure to require performance of any provision of the Section 4 shall constitute a waiver of that
provision as to that or any other instance. No waiver granted under the Section 4 of this Agreement as to any one provision herein shall constitute a subsequent waiver of such provision or of any other provision herein, nor shall it constitute
the waiver of any performance other than the actual performance specifically waived. 
 (e) Any other provisions of this
Agreement may be amended only by a written instrument signed by the Company and by persons holding a majority of the Company’s outstanding Ordinary Shares and Preference Shares, voting on an as-converted basis. Notwithstanding the foregoing,
the exhibits to this Agreement may be amended by the Company to add new Shareholders as permitted hereunder, adjust share amounts, modify number of Shareholders or to reflect transfers permitted hereunder. 

5.12 Facsimile Signatures. A facsimile or other electronic reproduction of this Agreement may be executed by one or more parties
and delivered by such party by facsimile or any similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen. Such execution and delivery shall be considered valid, binding and effective for all
purposes. 
 5.13 Attorneys’ Fees. In the event that any dispute among the parties to this Agreement should result
in litigation, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including, without
limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals. 
 [Remainder of this Page Intentionally Left Blank] 

  
 28 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’ Rights
Agreement as of the date first written above. 
  

			
	LOYALTY ALLIANCE ENTERPRISE CORPORATION
		
	By:	 	 /s/ Abraham Jou

		
	Name:	 	Abraham Jou
		
	Title:	 	Chairman of the Board and Director

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENTEmployment Agreement, William Hawkins

 Exhibit 10.11 
 Execution Version 
 EMPLOYMENT AGREEMENT

 AGREEMENT, effective as of October 17, 2011 (the “Agreement”), between Immucor, Inc.
(“Immucor”), IVD Holdings Inc. (“Parent,” and together with Immucor, the “Company”), and William Hawkins (the “Executive”). 

WHEREAS, the Company desires that the Executive serve the Company as its Chief Executive Officer, on the terms and conditions set forth
herein. 
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein and for other good and valuable
consideration, the parties agree as follows: 
 1. General. 

The parties agree that, subject to the terms hereof, the Executive shall serve as Chief Executive Officer of Immucor, and shall also be
Chief Executive Officer of Parent, after the Effective Date (as defined below) in accordance with the terms and conditions set out herein. 
 2. Employment, Duties and Agreements. 
 (a) The Company hereby agrees to employ
the Executive as its Chief Executive Officer, and the Executive hereby accepts such position and agrees to serve the Company in such capacity during the employment period fixed by Section 4 hereof (the “Employment Period”). In
addition, the Executive shall serve as a member of the Board of Directors of Parent (the “Board”). The Executive shall have such duties and responsibilities as are consistent with the Executive’s position and as may be assigned
by the Company from time to time. During the Employment Period, the Executive shall be subject to, and shall act in accordance with, all reasonable instructions and directions of the Board and all generally applicable written policies and rules of
the Company that are provided or made available to Executive. 
 (b) During the Employment Period, excluding any periods of
vacation and sick leave to which the Executive is entitled, the Executive shall devote his full working time, energy and attention to the performance of his duties and responsibilities hereunder (except as contemplated by Section 2(c) hereof)
and shall faithfully and diligently endeavor to promote the business and best interests of the Company. 
 (c) During the
Employment Period, the Executive may not, without the prior written consent of Parent, directly or indirectly, operate, participate in the management, operations or control of, or act as an executive, officer, consultant, agent or representative of,
any type of business or service (other than as an executive of the Company or advisor to TPG Capital, L.P. or its affiliates (“TPG”)); provided, that it shall not be a violation of the foregoing for the Executive to manage
his personal, financial and legal affairs so long as such activities do not unduly interfere with the performance of his duties and responsibilities to the Company as provided hereunder; and provided further, that Parent shall not
unreasonably withhold consent to the Executive serving as a director on the board of directors of one or more companies other than the Company whose activities are not in competition, directly or indirectly, with those of the Company and the amount
of time and attention required of the Executive to satisfy his obligations as such a director are not reasonably likely to detract from the execution of his duties and responsibilities hereunder in any material respect. Parent hereby consents to the
Executive serving on the boards of the entities listed on Schedule A hereto. 

  

 3. Compensation. 
 (a) As compensation for the agreements made by the Executive herein and the performance by the Executive of his obligations hereunder, during the Employment Period, the Company shall pay the Executive,
pursuant to the Company’s normal and customary payroll procedures, a base salary at the rate of $800,000 per annum (the “Base Salary”). 
 (b) In addition to the Base Salary, during the Employment Period, the Executive shall be eligible to earn an annual bonus (the “Annual Bonus”) in each fiscal year during the Employment
Period (including, for the avoidance of doubt, the fiscal year in which the Effective Date occurs), with a target Annual Bonus of 100% of Base Salary up to a maximum of 200% of Base Salary, based on the achievement of annual individual and Company
performance objectives established by the Board following consultation with the Executive during the first quarter for such fiscal year, subject to the Executive’s employment with the Company through the applicable payment date (which such date
shall occur as soon as reasonably practicable after the audited financial statements for the applicable fiscal year have been completed and delivered to the Company) (the “Payment Date”); provided, however, that in the event the Executive
terminates employment following the end of the fiscal year and prior to the Payment Date by reason of death, Disability, termination of employment by the Company without Cause or resignation by the Executive with Good Reason, the Executive shall be
deemed to have been employed on the Payment Date and such Annual Bonus will be paid to the Executive in a single lump sum as soon as reasonably practicable after the audited financial statements for the applicable fiscal year have been completed and
delivered to the Company, but in all events no later than March 15 of the calendar year following the end of fiscal year with respect to which the Annual Bonus is payable. 

(c) As soon as practicable after the Execution Date (as hereinafter defined), the Executive will receive a one-time nonrecurring grant of
options (the “Options”) to purchase 128,658 shares of common stock (“Shares”) of Parent, with each Option having an exercise price equal to the fair market value of a Share on the date of grant, which is expected to
be $100 per Share. With respect to the Options, 50% shall be Time-Vested Options, as such term is defined in the Option Agreements, and 50% shall be Performance-Vested Options, as such term is defined in the Option Agreements. The specific terms and
conditions governing all aspects of the Options shall be provided in the Company’s management equity incentive plan and in the Option grant agreement (collectively, the “Option Agreements”). 

(d) The Executive shall purchase 10,000 Shares from Parent (the “Investment”) and Parent shall issue such Shares to
Executive for an aggregate investment of one million dollars ($1,000,000), subject to Parent and Executive executing a subscription agreement reasonably satisfactory to Parent and Executive (the “Subscription Agreement”) and Parent
and Executive executing a Management Stockholders’ Agreement (as defined below) that is reasonably acceptable to Parent and Executive. $500,000 of the investment shall be made on or before December 31, 2011 at a price equal to $100 per
Share and $500,000 of the investment shall be made on or before June 30, 2012 at a price equal to $100 per Share. 
 (e)
The parties recognize that the purchase of any Shares upon the exercise of the Options, or any other purchase or issuance of Shares, including pursuant to the Investment as provided above, will be subject to the execution by Parent and Executive of
a Management Stockholders’ Agreement for Parent substantially in the form attached hereto as Exhibit A (the 

  
 2 

 
“Management Stockholders’ Agreement” and, together with the Option Agreements and the Subscription Agreement, the “Equity Agreements”). 

(f) During the Employment Period: (i) except as specifically provided herein, the Executive shall be eligible to participate in all
plans, practices, policies and programs (collectively, “Plans”) of the Company providing for savings or retirement benefits that are made available generally to other executive officers of the Company, subject to the terms of such
Plans, and (ii) except as specifically provided herein, the Executive and/or the Executive’s family, as the case may be, shall be eligible for participation in, and shall be eligible to receive all benefits under, all welfare benefit Plans
(including the Company’s disability Plan) provided by the Company that are made available generally to other executive officers of the Company (for the avoidance of doubt, such Plans shall not include any Plan that provides benefits in the
nature of severance or continuation pay), subject to the terms of such Plans. 
 (g) The Company shall reimburse the Executive
for all reasonable business expenses upon the presentation of statements of such expenses in accordance with the Company’s policies and procedures now in force or as such policies and procedures may be modified with respect to all senior
executive officers of the Company. Any reimbursement made pursuant to this Section 3(g) that would constitute nonqualified deferred compensation subject to Section 409A shall be made, if at all, promptly, but not later than the end of the
calendar year following the calendar year in which the expense was incurred. The Executive’s entitlement to any other reimbursements shall be subject to the terms and conditions of the Company’s reimbursement policy for executive officers,
which shall comply with the requirements of Section 409A to the extent applicable. 
 (h) Within 10 business days of the
Execution Date, the Company shall pay the Executive a cash signing bonus equal to $100,000 (the “Signing Bonus”); provided, that if the Executive terminates his employment with the Company without Good Reason within one year of the
Effective Date, the Executive shall repay the Signing Bonus to the Company within 20 business days of the date of such termination. In addition, the Company shall promptly reimburse the Executive for all reasonable and customary relocation expenses
that would be payable under a customary relocation expense policy for senior executives (“Relocation Expenses”) such as the Executive, with respect to expenses that he incurs within 24 months of the Effective Date as a direct result
of his initial relocation from his current primary residence in Minnesota to a location within reasonable commuting distance of the Company’s executive offices in the greater Atlanta, Georgia area (“Atlanta”), such as home-marketing
assistance for the Executive’s primary Minnesota residence; reimbursement of reasonable realtor’s fees and reasonable closing costs on the sale of such Minnesota residence; house-hunting visits to Atlanta for the Executive and/or his
spouse and dependants as reasonably necessary or desirable; up to six (6) months of temporary corporate housing in Atlanta as needed; regular commuting costs for Executive to travel between Minneapolis and Atlanta for up to six (6) months;
the cost of packing and moving the Executive’s household goods and the moving of all automobiles (unless the Executive chooses to drive one) from Minnesota to the Executive’s place of accommodation in Atlanta; the cost of temporary storage
of the Executive’s household goods for up to six (6) months; reasonable closing costs on a new primary residence in a reasonable commuting distance from the Company’s executive offices in Atlanta; and airfare to Atlanta for all
members of the Executive’s immediate family. For avoidance of doubt, such reimbursable Relocation Expenses will not include payment of any losses in connection with any capital transaction, such

  
 3 

 
as the sale of a home. In the event that any of the payments or benefits due to the Executive under this Section 3(h) are taxable to the Executive, the Company shall promptly make additional
“gross up” payments to the Executive sufficient to cover such additional taxes. Except with respect to the Signing Bonus, the Company shall pay the Executive any amounts due to him under this Section 3(h) within thirty (30) days
after submission of written documentation substantiating such amounts, but no later than December 31 of the year following the year in which they were incurred, and payment thereof shall be administered in compliance with Section 409A.

 (i) Within 10 business days of the Execution Date, the Company shall pay or reimburse the Executive for any and all
reasonable attorneys’ fees and related costs paid in connection with his negotiation and execution of this Agreement and any related agreements, up to a maximum amount of $25,000. 

4. Employment Period. 
 The Employment Period shall commence on October 17, 2011 (the “Effective Date”) and shall terminate on the fifth anniversary of the Effective Date, provided that on the fifth
anniversary of the Effective Date and on each anniversary thereafter, the Employment Period shall automatically be extended for additional one-year periods unless either party provides the other party with notice of non-renewal at least sixty
(60) days before any such anniversary (the anniversary date on which the Employment Period terminates shall be referred to herein as the “Scheduled Termination Date”). For greater certainty, a non-renewal notice given as
contemplated in this Section 4 shall be treated for all purposes of this Agreement as a termination of the Executive’s employment by the Company without Cause under Section 4(d) below. Notwithstanding the foregoing, the
Executive’s employment hereunder may be terminated during the Employment Period prior to the Scheduled Termination Date upon the earliest to occur of any one of the following events (at which time the Employment Period shall be terminated):

 (a) Death. The Executive’s employment hereunder shall terminate upon his death. 

(b) Disability. The Company shall be entitled to terminate the Executive’s employment hereunder for “Disability”
if, as a result of the Executive’s incapacity due to physical or mental illness or injury, the Executive shall have been unable to perform his duties hereunder for a period of one hundred eighty (180) consecutive days. 

(c) Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of this Agreement, the term
“Cause” shall mean: (i) willful misconduct of the Executive in connection with the performance of his duties hereunder; (ii) the Executive’s conviction of (or pleading guilty or pleading no contest or nolo
contendere to) a felony or comparable crime in any jurisdiction that does not classify crimes using the term “felony,” other than minor traffic offenses and other minor offenses that are not inconsistent with the Company’s
reasonable expectations of a person occupying the position of Chief Executive Officer; (iii) the Executive’s unauthorized removal, use or disclosure of the Company’s or any Affiliate’s confidential information that would
reasonably be expected to cause material harm (financial or otherwise) to the Company; (iv) the performance by the Executive of any material act or acts of dishonesty in connection with or relating to the Company’s or its Affiliates’
business; or (v) a material breach of any of the Executive’s material obligations under this Agreement; provided, that, in the case of any action or inaction by the Executive described in clause (iii), (iv)

  
 4 

 
or (v) above, the Executive shall, to the extent such action or inaction by the Executive is reasonably susceptible to cure, be given thirty (30) days after written notice by the
Company to the Executive to cure such action or inaction. 
 (d) Without Cause. The Company may terminate the Executive’s
employment hereunder during the Employment Period without Cause. 
 (e) Voluntarily. The Executive may voluntarily terminate his
employment hereunder, without Good Reason, provided that the Executive provides the Company with notice of his intent to terminate his employment at least 60 days in advance of the Date of Termination (as defined in Section 5 below). In the
event the Executive voluntarily terminates his employment pursuant to this Section 4(e), the Board may elect to waive the period of notice, or any portion thereof, and, if the Board so elects, the Company will pay the Executive his Base Salary
for the period so waived. 
 (f) For Good Reason. The Executive may terminate his employment hereunder for Good Reason (as
defined below), provided the Executive complies with the applicable notice and cure provisions set forth in Sections 5 and 6(a) hereof. 
 5. Termination Procedure. 
 (a) Notice of Termination. Any termination of the
Executive’s employment by the Company or by the Executive during the Employment Period (other than a termination on account of the death of Executive) shall be communicated by written “Notice of Termination” to the other party
hereto in accordance with Section 11(a). 
 (b) Date of Termination. “Date of Termination” shall mean
(i) if the Executive’s employment is terminated by his death, the date of his death, (ii) if the Executive’s employment is terminated pursuant to Section 4(b), on the date the Executive receives Notice of Termination from
the Company, (iii) if the Executive voluntarily terminates his employment (whether or not for Good Reason), the date specified in the Notice of Termination, which shall not be less than 60 days after the Notice of Termination is delivered to
the Company, and (iv) if the Executive’s employment is terminated for any other reason, the date on which a Notice of Termination is given or any later date (within thirty (30) days, or any alternative time period agreed upon by the
parties, after the giving of such notice) set forth in such Notice of Termination. 
 6. Termination Payments. 

(a) Without Cause or for Good Reason. In the event the Employment Period terminates under this Agreement as a result of the Company
terminating the Executive’s employment without Cause or the Executive terminating his employment for Good Reason, including, without limitation, as a result of a non-renewal notice under Section 4 hereof, the Company shall pay the
Executive (A) within thirty (30) days following the Date of Termination, the Executive’s accrued but unused vacation or other paid time off, Base Salary through the Date of Termination (to the extent not theretofore paid),
reimbursement of business expenses contemplated by Section 3(g) hereof (appropriately documented in accordance with the Company’s reimbursement policies), and any payments required to be made under Section 3(h) hereof (collectively,
the “Accrued Benefits”), (B) two (2) times the Executive’s Base Salary, payable in substantially equal installments over a twenty four (24)-month period in accordance with the Company’s standard payroll
practices, (C) the Annual Bonus relating to the prior fiscal year to the extent then unpaid (as described in Section 3(b)), and (D) a pro-rated Annual Bonus 

  
 5 

 
for the year in which the termination occurs equal to the Annual Bonus for such year that the Executive would have received based on actual performance had he remained employed through the date
required under Section 3(b) in order for such Annual Bonus to be paid, multiplied by a fraction, the numerator of which is equal to the number of days the Executive was employed by the Company in the year of termination and the denominator of
which is 365, which amount shall be paid as soon as reasonably practicable after the audited financial statements for the applicable fiscal year have been completed and delivered to the Company but in all events not later than March 15 of the
year following the year in which such termination occurs. For the eighteen (18)-month period commencing on the day after Executive’s Date of Termination, if the Executive elects COBRA continuation coverage, the Company shall continue to provide
medical benefits to the Executive which are substantially similar to those provided generally to executive officers of the Company (including any required contribution by such executive officers) pursuant to such medical plan as may be in effect
from time to time as if the Executive’s employment had not been terminated (it being understood that the Company will provide such coverage by paying the Executive’s COBRA premiums, less any contribution required to be paid by the
Executive for coverage of the Executive, his spouse and dependents under a Company group health plan); provided, however, that if the Executive becomes re-employed with another employer and is eligible to receive comparable medical or
other welfare benefits under another employer-provided plan, the corresponding medical and other welfare benefits described herein shall be terminated. The Executive shall promptly notify the Company of any changes in his medical benefits coverage.
The payments and benefits provided under this Section 6(a) other than the Accrued Benefits are subject to and conditioned upon the Executive validly executing a release and waiver in the form attached as Exhibit B (the
“Release”) and the Release becoming effective within sixty (60) days of the Date of Termination. For the avoidance of doubt, upon a termination of the Employment Period without Cause or as a result of Good Reason, the Executive
shall not be entitled to any other compensation or benefits not expressly provided for in this section or in the Equity Agreements, regardless of the time that would otherwise remain in the Employment Period had the Employment Period not been
terminated without Cause or for Good Reason. Except as provided in this Section 6(a), or pursuant to Section 3(c) if applicable, and except for any vested benefits under any tax qualified pension plans of the Company, and continuation of
health insurance benefits on the terms and to the extent required by Section 4980B of the Internal Revenue Code of 1986 and Section 601 of the Employee Retirement Income Security Act of 1974, as amended (which provisions are commonly known
as “COBRA”) or such other analogous legislation as may be applicable to the Executive, the Company shall have no additional obligations under this Agreement. For purposes of this Agreement, “Good Reason” shall mean,
without the Executive’s written consent: (i) any materially adverse change in the Executive’s title, authority, duties or responsibilities, (ii) any change in the Executive’s reporting responsibility such that he reports to
any person or group of persons other than the Board, (iii) Executive not being elected or appointed to the board of directors of Parent and Immucor, or Executive’s removal as such a director of Parent or Immucor, (iv) any reduction,
either from one year to the next, or within the current year, in the Executive’s base salary or bonus opportunity, other than a decrease in base salary or bonus opportunity of not more than 10% (in the case of each of base salary and bonus
opportunity) that applies similarly to at least five other executives of Immucor or (v) a change of the Executive’s principal place of business to a location more than 50 miles from its present location; provided, that Good Reason
shall not occur unless the Executive shall have given a detailed written notice to the Company of any fact 

  
 6 

 
or circumstance believed by the Executive to constitute Good Reason within sixty (60) days of the occurrence of such fact or circumstance, and to the extent any action or inaction by the
Company is reasonably susceptible to cure, the Company shall have thirty (30) days to cure such fact or circumstance and shall have failed to so cure. 
 (b) Change of Control. Subject to Section 11(m)(ii), in the event the Employment Period terminates under this Agreement as a result of the Company terminating the Executive without Cause or the
Executive terminating his employment for Good Reason within twenty four (24) months following a transaction or event constituting a Change of Control (as such term is defined in the Option Agreements), (A) the Company shall provide the
Executive with all payments and benefits described in Section 6(a) (according to the schedule specified for each such payment and benefit in Section 6(a)), (B) the Company shall pay the Executive an amount equal to two (2) times
the Executive’s target Annual Bonus for the year in which the termination occurs (payable according to the schedule specified in Section 6(a)(B)), regardless of whether the performance objectives contemplated by Section 3(b) have been
met, and (C) the Time-Vested Options and any other equity-based bonus or award that vests solely on the basis of time held by the Executive at the time of such termination (including any replacement or substitute options or other equity-based
bonus or award that vests solely on the basis of time received in connection with such Change of Control ) will automatically and fully vest immediately upon such termination of employment. Any amount payable under clauses (A) and
(B) above in this Section 6(b) other than the Accrued Benefits shall be subject to and conditioned upon the Executive executing the Release and the Release becoming effective within sixty (60) days of the Date of Termination.

 (c) Cause or Voluntarily Other than for Good Reason. If the Executive’s employment is terminated during the Employment
Period by the Company for Cause or voluntarily by the Executive other than for Good Reason, the Company shall pay the Executive within thirty (30) days following the Date of Termination the Accrued Benefits. Except as provided in this
Section 6(c) or Section 6(f), or pursuant to Section 3(c) if applicable, and except for any vested benefits under any tax qualified pension plans of the Company, and continuation of health insurance benefits on the terms and to the
extent required by COBRA or any other analogous legislation as may be applicable to the Executive, the Company shall have no additional obligations to make payments under this Agreement. 

(d) Disability or Death. If the Executive’s employment is terminated during the Employment Period as a result of the
Executive’s death or Disability, the Company shall pay the Executive or the Executive’s estate, as the case may be, (i) within thirty (30) days following the Date of Termination, the Accrued Benefits and (ii) the Annual
Bonus as described in Section 3(b), if applicable, at the time set forth in Section 3(b). Except as provided in this Section 6(d), or pursuant to Section 3(b), 3(c) or 6(f) if applicable, and except for any vested benefits under
any tax qualified pension plans of the Company, and continuation of health insurance benefits on the terms and to the extent required by COBRA or any other analogous legislation as may be applicable to the Executive, the Company shall have no
additional obligations to make payments under this Agreement. 
 (e) Release. In the event the Executive receives termination
payments and benefits under this Agreement that are conditioned on the execution and non-revocation of the Release and the Executive does not execute the Release in the time and manner set forth above following the Executive’s termination of
employment, the Executive shall promptly pay to the 

  
 7 

 
Company, together with interest from the date of payment to the date of repayment at the prime rate, such amounts or the value of such benefits so received. For the avoidance of doubt, in no
event shall Executive be required to execute the Release as a condition to receiving the Accrued Benefits, any vested benefits under any tax qualified pension plans of the Company, the continuation of health insurance benefits on the terms and to
the extent required by COBRA or any other similar law, any accrued rights or benefits under the Equity Agreements to the extent payable after the execution of the Release, or any other benefit that is payable pursuant to its terms after the
execution of the Release. The Release creates legally binding obligations on the part of the Executive and the Company therefore advises the Executive to seek the advice of an attorney before signing it. 

(f) Benefits. Upon termination of employment for any reason, the accrued benefits under any Plans or otherwise under Section 3(f)
hereof shall be paid in accordance with the applicable Plans, documents and Company policy. 
 7. Legal Fees; Directors’
and Officers’ Liability Insurance. 
 (a) In the event of any contest or dispute between the Company and the Executive with
respect to this Agreement or the Executive’s employment hereunder, each of the parties shall be responsible for its respective legal fees and expenses. 
 (b) During the Employment Period, the Company shall purchase and maintain reasonable and customary directors’ and officers’ liability insurance coverage covering the Company and the Executive.
Parent and Immucor shall also enter into an indemnification or similar agreement with Executive on the same terms as Parent or Immucor provides to any other director of Parent or Immucor (if any). 

8. Non-Solicitation. 
 During the Employment Period and for eighteen (18) months thereafter, the Executive hereby agrees not to, directly or indirectly, solicit or hire or assist any other person or entity in soliciting or
hiring any employee of Parent or Immucor or any of their subsidiaries (the “Immucor Group”) to perform services for any entity (other than a member of the Immucor Group), or attempt to induce any such employee to leave the employ of
any member of the Immucor Group, or interfere in any manner with any such employee’s employment relationship with any member of the Immucor Group, or solicit on behalf of himself or any other Person (as defined below) anyone who was employed by
any member of the Immucor Group during the six-month period preceding such solicitation, hiring or engagement. Nothing herein shall preclude the Executive or such other person or entity from using any public advertising of a nature or in a manner
not specifically directed to employees of any member of the Immucor Group to solicit or hire employees of any member of the Immucor Group or their respective affiliates if such employees initiate contact with the Executive further to such
advertising without specific solicitation. For the avoidance of doubt, in no event will any solicitation or hiring by any company that Executive becomes employed by, serves as an agent or consultant to, or becomes a partner, member, principal,
stockholder or other owner of, be considered a breach of this Section 8 provided that Executive does not participate in such solicitation or hiring decision. 
 9. Confidentiality; Non-Compete; Non-Disclosure; Non-Disparagement. 
 (a) The
Executive hereby agrees that, during the Employment Period and thereafter, he will hold in strict confidence any proprietary or Confidential Information related to 

  
 8 

 
Parent, Immucor or their respective affiliates. For purposes of this Agreement, the term “Confidential Information” shall mean all information of Parent, Immucor or their respective
affiliates (in whatever form) which is not generally known to the public, including without limitation any inventions, processes, methods of distribution, customer lists or customers’ names, or trade secrets, but shall exclude information that:

  

	 	(i)	is or becomes generally available to the public other than as a result of disclosure directly or indirectly by the Executive in breach of his or her obligations;

  

	 	(ii)	is or becomes available to the Executive on a non-confidential basis from a source other than the Executive unless the Executive knows after due inquiry that such
source is prohibited from disclosing the information to the Executive by a contractual, fiduciary or other legal obligation to the Company or any of its affiliates; or 

 

	 	(iii)	is or was independently acquired or developed by the Executive after the termination of his or her employment without violating the Executive’s obligations under
this Agreement or any other obligation of confidentiality the Executive may have to the Company or any of its affiliates. 

 (b) The Executive and the Company agree that Parent, Immucor or their respective affiliates would likely suffer significant harm from the Executive’s competing with any member of the Immucor Group
during the Employment Period and for some period of time thereafter. Accordingly, the Executive agrees that he will not, during the Employment Period and for a period of eighteen (18) months following the termination of the Employment Period,
directly or indirectly, become employed by, serve as an agent or consultant to, become a partner, member, principal, stockholder or other owner (other than a holder of less than 1% of the outstanding voting shares of any publicly held company) of,
any Person engaged in the business of developing and manufacturing instrument-reagents systems used to detect and identify cell and serum components of human blood prior to blood transfusions (the “Business”) in a manner that
competes with the business activities of any member of the Immucor Group at the time of the termination (whether or not for compensation). For purposes of this Agreement, the term “Person” shall mean any individual, partnership,
corporation, limited liability company, unincorporated organization, trust or joint venture, or a governmental agency or political subdivision thereof that is engaged in, or otherwise competes with, the Business in any jurisdiction in which any
member of the Immucor Group engages in the Business at the time of termination or where any member of the Immucor Group’s customers are located at the time of termination. 

(c) The Executive hereby agrees that, upon the termination of the Employment Period, he shall not knowingly take, without the prior
written consent of the Company, any drawing, blueprint, specification or other document (in whatever form) of the Company or any of its affiliates, which is of a confidential nature relating to the Company or any of its affiliates, or, without
limitation, relating to its or their methods of distribution, or any description of any formulas or secret processes and will return any such information (in whatever 

  
 9 

 
form) then in his possession (or, if he discovers that such information is in his possession after the termination of his employment, promptly after such discovery). 

(d) The Executive hereby agrees not to defame or disparage any member of the Immucor Group and any of the officers, directors, members or
executives of the foregoing. Parent and Immucor each agree not to defame or disparage the Executive in any authorized corporate communications, and that, following the termination of the Executive’s employment, each will instruct its executive
officers, directors and senior management not to disparage the Executive. 
 10. Injunctive Relief. It is impossible to measure
in money the damages that will accrue to Parent, Immucor or any of their respective affiliates in the event that the Executive breaches any of the restrictive covenants provided in Sections 8 and 9 hereof. In the event that the Executive breaches
any such restrictive covenant, Parent, Immucor or any of their respective affiliates shall be entitled to an injunction restraining the Executive from violating such restrictive covenant (without posting any bond). If Parent, Immucor or any of their
respective affiliates shall institute any action or proceeding to enforce any such restrictive covenant, the Executive hereby waives the claim or defense that Parent, Immucor or any of their respective affiliates has an adequate remedy at law and
agrees not to assert in any such action or proceeding the claim or defense that Parent, Immucor or any of their respective affiliates has an adequate remedy at law. The foregoing shall not prejudice Parent’s, Immucor’s or any of their
respective affiliates’ right to require the Executive to account for and pay over to Parent, Immucor or any of their respective affiliates, and the Executive hereby agrees to account for and pay over, the compensation, profits, monies, accruals
or other benefits derived or received by the Executive as a result of any transaction constituting a breach of any of the restrictive covenants provided in Sections 8 and 9 hereof. The Executive agrees that the periods of restriction in Sections 8
and 9(b) shall be tolled, and shall not run, during any period of time in which he is in violation of the terms thereof as determined by any court of competent jurisdiction, in order that the Parent, Immucor and their respective affiliates shall
have all of the agreed-upon temporal protection recited herein. The parties further agree that, in the event that any provision of Section 8 or 9 hereof shall be determined by any court of competent jurisdiction to be unenforceable by reason of
its being extended over too great a time, too large a geographic area or too great a range of activities, such provision shall be deemed to be modified to permit its enforcement to the maximum extent permitted by law. 

11. Miscellaneous. Any notice or other communication required or permitted under this Agreement shall be effective only if it is in
writing and shall be deemed to be given when delivered personally or four days after it is mailed by registered or certified mail, postage prepaid, return receipt requested or one day after it is sent by a reputable overnight courier service and, in
each case, addressed as follows (or if it is sent through any other method agreed upon by the parties): 

  
 10 

 (a) 
 If to the Company: 
 Immucor, Inc. 

3130 Gateway Drive 
 P.O. Box 5625 
 Norcross, GA 30091-5625 

Attn: General Counsel 
 with a copy to: 
 Loretta Richard 

Ropes & Gray LLP 
 Prudential Tower 
 800 Boylston St. 

Boston, MA 02199 

If to Parent: 

IVD Holdings Inc. 

c/o Immucor, Inc. 

3130 Gateway Drive 
 P.O. Box 5625 
 Norcross, GA 30091-5625 

Attn: General Counsel 
 with a copy to: 
 Loretta Richard 

Ropes & Gray LLP 
 Prudential Tower 
 800 Boylston St. 

Boston, MA 02199 

If to the Executive: 
 William Hawkins, 
 at the address listed in the Company’s records. 

or to such other address as any party hereto may designate by notice to the others. 

(b) This Agreement shall constitute the entire agreement among the parties hereto with respect to the Executive’s employment
hereunder, and supersedes and is in full substitution for any and all prior understandings or agreements with respect to the Executive’s employment (it being understood, however, that any Options, Investment and Shares shall be governed by the
relevant Equity Agreements and any agreements or commitments by TPG shall be governed by any written letter or agreement signed by TPG in favor of the Executive). 

  
 11 

 (c) This Agreement may be amended only by an instrument in writing signed by the parties
hereto, and any provision hereof may be waived only by an instrument in writing signed by the party or parties against whom or which enforcement of such waiver is sought. The failure of any party hereto at any time to require the performance by any
other party hereto of any provision hereof shall in no way affect the full right to require such performance at any time thereafter, nor shall the waiver by any party hereto of a breach of any provision hereof be taken or held to be a waiver of any
succeeding breach of such provision or a waiver of the provision itself or a waiver of any other provision of this Agreement. 

(d) The parties hereto acknowledge and agree that each party has reviewed and negotiated the terms and provisions of this Agreement and
has had the opportunity to contribute to its revision. Accordingly, the rule of construction to the effect that ambiguities are resolved against the drafting party shall not be employed in the interpretation of this Agreement. Rather, the terms of
this Agreement shall be construed fairly as to both parties hereto and not in favor or against either party. 
 (e) The parties
hereto hereby represent that they each have the authority to enter into this Agreement, and each party hereby represents to the other that the execution of, and performance of duties under, this Agreement shall not constitute a breach of or
otherwise violate any other agreement to which such party is a party. The Executive hereby further represents to the Company that he will not utilize or disclose any confidential information obtained by the Executive in connection with any former
employment with respect to his duties and responsibilities hereunder. 
 (f) This Agreement is binding on and is for the benefit
of the parties hereto and their respective successors, permitted assigns, heirs, executors, administrators and other legal representatives. Neither this Agreement nor any right or obligation hereunder may be assigned by the Executive or the Company;
provided, however, that the Company may assign this Agreement to any subsidiary of Parent or Immucor in connection with a reorganization or to any entity that purchases substantially all the assets of the Company provided that such
entity assumes all of the obligations of the Company under this Agreement. 
 (g) The Company shall require any successor
(whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume this Agreement in the same manner and to the same extent that the Company would have
been required to perform it if no such succession had taken place. As used in the Agreement, “the Company” shall mean both the Company as defined above and any such successor that assumes this Agreement, by operation of law or otherwise;
provided, however, that the obligations of the Executive under Section 9(b) shall only apply to the Business as it relates to Immucor’s business at the time immediately before such transaction is consummated. 

(h) Any provision of this Agreement (or portion thereof) which is deemed invalid, illegal or unenforceable in any jurisdiction shall, as
to that jurisdiction and subject to this Section, be ineffective to the extent of such invalidity, illegality or unenforceability, without affecting in any way the remaining provisions thereof in such jurisdiction or rendering that or any other
provisions of this Agreement invalid, illegal, or unenforceable in any other jurisdiction. If any covenant should be deemed invalid, illegal or unenforceable because its scope is considered excessive, such covenant shall be modified so that the
scope of the covenant is 

  
 12 

 
reduced only to the minimum extent necessary to render the modified covenant valid, legal and enforceable. No waiver of any provision or violation of this Agreement by the Company shall be
implied by the Company’s forbearance or failure to take action. 
 (i) The Company may withhold from any amounts payable to
the Executive hereunder all federal, state, city or other taxes that the Company may reasonably determine are required to be withheld pursuant to any applicable law or regulation (it being understood, that the Executive shall be responsible for
payment of all taxes in respect of the payments and benefits provided herein). 
 (j) This Agreement shall be governed by and
construed in accordance with the laws of the State of Georgia without reference to its principles of conflicts of law. 
 (k)
This Agreement may be executed in several counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument. A facsimile or other electronic transmission of a signature shall be deemed to be and
have the effect of an original signature. 
 (l) The headings in this Agreement are inserted for convenience of reference only
and shall not be a part of or control or affect the meaning of any provision hereof. 
 (m) The Executive and the Company
acknowledge that they intend that the compensation arrangements set forth in this Agreement comply with the requirements of, or the requirements of an exemption from, Section 409A of the Internal Revenue Code (together with the regulations
thereunder, “Section 409A”), and the Agreement shall be construed in accordance therewith. 
  

	 	(i)	For purposes of this Agreement, all references to “termination of employment” and similar or correlative phrases shall be construed to require a
“separation from service” (as defined in Section 1.409A-1(h) of the Treasury regulations after giving effect to the presumptions contained therein), and the term “specified employee” means an individual determined by the
Company to be a specified employee under Treasury regulation Section 1.409A-1(i). 

  

	 	(ii)	If any payment or benefit hereunder constituting “nonqualified deferred compensation” subject to Section 409A would be subject to subsection (a)(2)(B)(i)
of Section 409A (relating to payments made to specified employees of publicly-traded companies upon separation from service), any such payment or benefit to which the Executive would otherwise be entitled during the six (6) month period
following the Executive separation from service will instead be provided or paid without interest on the first business day following the expiration of such six (6) month period, or if earlier, the date of the Executive’s death.

  

	 	(iii)	Each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as
a right to a series of separate payments. 

  
 13 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of this 8th day of December, 2011 (the
“Execution Date”). 
  

	
	William Hawkins
	
	/s/ William Hawkins

  

	
	Immucor, Inc.
	
	/s/ Todd B. Sisitsky
	Name: Todd B. Sisitsky
	Title: Authorized Signatory

  

	
	IVD Holdings, Inc.
	
	/s/ Todd B. Sisitsky
	Name: Todd B. Sisitsky
	Title: Authorized Signatory

 [Signature Page to Hawkins Employment Agreement] 

  

 Schedule A 

List of Permitted Boards 
  

	1.	KeraNetics, LLC (including direct or indirect parent companies and subsidiaries) 

 

	2.	Thoratec Corporation (including direct or indirect parent companies and subsidiaries) 

 

	3.	Duke University Board of Trustees 

  

 Exhibit A 
 MANAGEMENT STOCKHOLDERS’ AGREEMENT 

  

 Exhibit B 

Form of Release 
 We advise you
to consult an attorney before you sign this release (the “Release”). You have until the date which is seven (7) days after the Release is signed and returned to Immucor, Inc. (“Immucor”) to change your mind and
revoke the Release. The Release shall not become effective or enforceable until after that date. 
 In consideration for the payments and
benefits (if any) provided under Section 6 of your Employment Agreement with Immucor and IVD Holdings Inc. dated as of October 17, 2011 (the “Agreement”) in connection with the termination of your employment that are
conditioned on your executing this Release and the Release becoming effective within sixty (60) days of the date of termination of your employment (such payments and benefits collectively, the “Separation Payments”), by your
signature below, you, for yourself and on behalf of your heirs, executors, agents, representatives, successors and assigns, hereby release and forever discharge Immucor, Parent, and their past and present subsidiaries, divisions and subdivisions
(collectively, the “Company”) and the Company’s past, present and future parent corporations, affiliates, related companies, agents, directors, officers, employees, representatives, assigns, stockholders, attorneys, insurers,
employee benefit programs (and the trustees, administrators, fiduciaries and insurers of such programs), and any other persons acting by, through, under or in concert with any of the persons or entities listed herein, and their successors
(hereinafter “those associated with the Company”) with respect to any and all claims, demands, actions and liabilities, whether in law or equity, which you may now have against the Company or those associated with the Company of whatever
kind, including but not limited to, those arising out of your employment with the Company or the termination of that employment. You agree that the Release covers, but is not limited to, claims arising under the Age Discrimination in Employment Act
of 1967, 29 U.S.C. § 621 et seq., Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., the Americans with Disabilities Act of 1990, 42 U.S.C. § 12101 et seq., the Fair Labor Standards Act, 29 U.S.C. § 201 et
seq., the Employee Retirement Income Security Act of 1974, 29 U.S.C. § 1001 et seq., the Family and Medical Leave Act of 1993 and any local, state or federal law, regulation or order, including without limitation those providing workers’
compensation benefits, restricting an employer’s right to terminate employees or otherwise regulating employment, enforcing express or implied employment contracts or requiring an employer to deal with employees fairly or in good faith, or
dealing with discrimination in employment on the basis of sex, race, color, national origin, veteran status, marital status, religion, disability, handicap, or age. You also agree that the Release includes claims based on wrongful termination of
employment, breach of employment contract (express or implied), tort related to Executive’s employment, or claims otherwise related to your employment or termination of employment with the Company and any claim for attorneys’ fees,
expenses or costs of litigation. 
 This Release covers all claims set forth above based on any facts or events, whether known or unknown by
you, that occurred on or before the date of this Release. You expressly waive all rights you might have under any law that is intended to protect you from waiving unknown claims and by your signature below indicate your understanding of the
significance of doing so. Except to challenge the Release or to enforce claims not covered by the Release, you agree that you will, after the date of this Release, never commence, prosecute, or cause to be commenced or

 
prosecuted any lawsuit or proceeding of any kind against the Company or those associated with the Company in any forum and agree to withdraw with prejudice all complaints or charges, if any, that
you have filed against the Company or those associated with the Company with respect to rights waived and released by this Release. 
 Anything
in this Release to the contrary notwithstanding, this Release does not include a release of: (i) any rights you have to the Accrued Benefits or the Separation Payments; (ii) any rights you may have to indemnification or other related
protections under any agreement, insurance policy, law, Company organizational document (e.g., articles or certificate of incorporation or by-laws) or policy, or otherwise; (iii) any rights you may have to equity, compensation or
benefits under the Company’s benefit plans that were accrued and unpaid prior to the date hereof and are payable hereafter (except to the extent any benefit claims were denied prior to the date of the release, as provided above); (iv) any
rights or claims that arise after you sign this Release, including, without limitation, under the Agreement; (v) any rights or claims against those associated with the Company that do not relate to your employment with the Company or the
termination of that employment, including, without limitation, any rights or benefits described in (the letter agreement between TPG Capital, L.P. and you dated December 12, 2011 or provided by any portfolio company as described therein;
(vi) any rights or claims under the Equity Agreements (as defined in the Agreement), related to the Options or the Investment (each as defined in the Agreement), or under the letter agreement between IVD Holdings Inc. and you dated
December 12, 2011; (vii) any rights to continuation of health insurance benefits on the terms and to the extent required by COBRA or any other similar law or (viii) your right to challenge the Release or pursue any of the foregoing
rights described in this paragraph. 
 You and the Company also agree that this Release will not affect the rights and responsibilities of the
United States Equal Employment Opportunity Commission (“EEOC”) and/or state or local fair employment practices agencies to enforce the anti-discrimination laws of the United States or the states in which you provided services to the
Company, and that nothing in this Agreement prevents you from filing, cooperating with, or participating in any proceeding before the EEOC or any state or local fair employment practices agency. However, you represent and warrant that you
knowingly and voluntarily waive all rights and claims arising prior to your execution of this Release, as well as rights to any payment, benefit, attorneys’ fees or other remedial relief as a consequence of any charge filed with or by the EEOC
or analogous state or local agency relating to any rights or claims arising prior to your execution of this Release and/or any litigation pursued by the EEOC or analogous state or local agency concerning any facts alleged in any such
charge. Nothing in this Agreement prevents you from complying with a lawful subpoena or court order. 
 By signing the Release, you further
agree as follows: 
 i. You have read the Release carefully and fully understand its terms; 

ii. You have had at least twenty-one (21) days to consider the terms of the Release; 
 iii. You have seven (7) days from the date you sign this Release to revoke it by written notification to the Company. After this seven (7)-day period, this Release is final and binding and may not be
revoked; 

  
 2 

 iv. You have been advised to seek legal counsel and have had an opportunity to do so; 

v. You would not otherwise be entitled to the benefits provided under your Agreement had you not agreed to execute the Release; and 

vi. Your agreement to the terms set forth above is voluntary. 

 

	
	William Hawkins
	Signature: ____________________________
	Dated: ____________________________

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}]]